Variables	Results

Demographic variables:

 Age, years	53.3 (8.7) (28–68)

 Gender, F/M	34 (82.9)/ 7 (17)

Cardiovascular risk factors:

 Family history of CVD	20 (48.8)

 Current/Ex-smokers	23 (56.1)

 Hypertension	17 (41.5)

 Diabetes	3 (7.3)

 CKD3a (eGFR 45–59 ml/min/1.73 m2)	2 (4.9)

 AI abnormal	11 (26.8)

 BMI > 30 kg/m2	5 (12.2)

 Physical inactivity	23 (56.1)

RA related variables

 Disease duration, years	19.2 (9.2) (8–45)

 Erosions (X-ray of hands/feet)	35 (85.4)

 Extra-articular symptoms	28 (68.3)

 Positive RF-IgM	33 (80.5)

 Positive anti-CCP2	30 (73.2)

 ESR, mm/h	19.2 (16.0) (2–64)

 CRP, mg/l	14.35 (37.5) (0.1–228.5)

 Average CRP (6 years), mg/l	11.02 (9.9) (0.9–37.3)

 Low RA activity (DAS28 ≤ 3.2)	23 (56.1)

 Current glucocorticoid use	18 (43.9)

 Current conventional synthetic DMARD	39 (95.1)

 Current biological DMARD	32 (78.1)


Source	F statistic	p	Estimated means (standard error)

Talker variability	0.505	0.481	0 4.351 (0.101) single-talker

			4.289 (0.089) multiple-talker

Talker Variability × Modality of Presentation	0.000	0.988	4.282 (0.143) audio only single-talker

			4.221 (0.125) audio only multiple-talkers

			4.420 (0.143) audio-visual single-talker

			4.357 (0.125) audio-visual multiple-talkers

Modality of presentation	0.653	0.423	4.252 (0.120) audio-only

			4.389 (0.120) audio-visual


Patients (n = 458)

Baseline characteristics	 	% or mean	(n or SD)

Men%	 	24.9	(114)

Women%	 	74.7	(342)

Age mean years (SD)	 	54.0	(7.4)

Weight mean kg (SD)	 	96.4	(18.3)

Starting BMI mean kg/m2 (SD)	 	36.0	(5.9)

Starting BMI kg/m2%	<30	9.8	(45)

 	30-34	43.9	(201)

 	35-39	23.8	(109)

 	≥40	21.2	(97)

 	not recorded	1.3	(6)

Smoking status%	smoker	14.4	(66)

 	not recorded	18.8	(86)

Diabetes Status%	diabetic	11.6	(53)

 	not recorded	15.7	(72)


Complication	EN group(n = 8)	EN+PN group(n = 9)

Surgery related complications

 Pancreatic leakage (minor leakage)	0	1

 Anastomotic leakage (minor leakage)	1	0

 Ileus	1	0

 Ulcer at anastomotic portion	0	1

 Wound infection	3	1

General complications

 Pulmonary	1	0

Total number of patients with complications	5	4

Mortality	1	0

No significant differences noted.


Category	Age (years)	Hb (g/dL)	Parasite density (% of parasitized RBCs)

Complicated cases	2.384 (±1.239)	9.579 (±0.900)	10.542 (±2.704)

Uncomplicated controls	2.796 (±1.315)	12.338 (±1.278)	7.596 (±2.040)

P value	0.007	<0.0001	<0.0001


Patients/reference group	Mean	SD	Comment Original publication

MS	35.4	12.1	Present data

Stroke	42.1	12.7	Present data

Male, age 40–49	64.2	16.3	German Health Survey 1998 (20) (N = 6964 participants, age 18–80)

Male, age 50–59	61.5	18.1	German Health Survey 1998 (20)

Female, age 40–49	57.4	18.8	German Health Survey 1998 (20)

Female, age 50–59	57.7	18.8	German Health Survey 1998 (20)


Parameter	Leaf oil 	Bark oil

Specific gravity (20°C) 	1.030–1.050 	1.010–1.030

Optical rotation (°) (20°C) 	1°96′–0°40′	Slightly laevorotatory

Refractive index (20°C) 	1.529–1.537 	1.573–1.591

Aldehyde content 	4% 	65–76%

Eugenol content 	77.3–90.5% 	4–10%

Solubility characteristics 	Soluble in 1.5 volumes of 70% alcohol 	Soluble in 2.0–3.0 volumes of 70% alcohol


Degree of comfort	Attending to patients with mental illness	Dealing with mentally sick people

	Frequency	Percent	Frequency	Percent

Extremely uncomfortable	22	19.8	28	25.2

Uncomfortable	54	48.6	41	36.9

Comfortable	31	27.9	37	33.3

Extremely comfortable	4	3.6	5	4.5

TOTAL	111	100.0	111	100.0


	ATIC mRNA expression△	p value

Variable	Low (117)	high (117)	(chi-square)

Gender

 Male	83	81	0.8865

 Female	34	36

Diagnosis Age

≤ 50	23	30	0.3488

> 50	94	87

AFP (ng/mL)

≤ 200	97	74	0.0011*

> 200	20	43

Hepatitis status

 Negative	61	44	0.0352*

 Positive	56	73

Vascular Invasion

 No	85	69	0.0384*

 Yes	32	48

Histologic Grade

 G1	17	9	0.0006*

 G2	64	43

 G3-G4	36	65

TNM stage

 I	78	56	0.0086*

 II	24	31

 III-IV	15	30


Component	Changes in SLE T cells	Reference

TCRζ

	Decreased TCRζ expression/phosphorylation	Grammatikos et al. (26), Kyttaris et al. (27), Pang et al. (29), and Takeuchi et al. (28)

	3′ UTR variants leading to instable versions of TCRζ	Chowdhury et al. (30), Gorman et al. (31), and Tsuzaka et al. (32)

Syk

	Replaces canonical ZAP-70	Krishnan et al. (33) and Tanaka et al. (34)

	More potent signal transduction	Tanaka et al. (34)

	Increased expression: inability of CREMα to repress transcription	Ghosh et al. (35)

Calcium signaling

	Increased recruitment of NFATc2 into the nucleus	Kyttaris et al. (36)

→ Elevated expression of CD154

	Enhanced nuclear import of CAMK IV	Juang et al. (37)

→ Elevated expression of CREMα

Other signaling components

	LAT displaced from lipid rafts	Abdoel et al. (38)

	Aberrant phosphorylation of Erk	Cedeno et al. (39) and Yi et al. (40)

Genes identified by GWAS

	UBASH3A	Diaz-Gallo et al. (41)

PP2AC	Katsiari et al. (42), and Tan et al. (43)

	TNFAIP3	Graham et al. (44)

SLAM	Morel et al. (45)


Days	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5	Scenario 6	Scenario 7

1	●	●	●	●	●	●	●

2	●	●	●	●	●	●	●

3	●	● (± α h)	○	●	●1	●	●

4	●1	●1	●	●1	●1	○	● (+ 4 h)1

5	●1	●1	●	● (± β h)1	●1	●1	●1

6	●1	●1	●1	●1	○1	●1	●1

n	24	24	24	24	24	24	72

t (h)	24	24	24	24	24	24	72 (-4)

ni (X-ray)	70	52	24	60	69 (+24)	48	65

CTT (h)	70	52	24	60	93	48	61.4


Feature	Wheeled Vehicle	Tracked Vehicle	Low-Altitude Helicopter

Car	Truck	SUV	Van

Weight (kg)	1,425	6,800	1,635	1,713	40,200	3,850

Number of Cylinders	4	6	4	5	10	8

Engine Capacity	78	170	110	140	3,240	1,468


 	Recognition rates (%)

Method	No. of training samples	Average recognition rates (%)

 	3	4

GWT	79.65	82.5	81.1

KDCV	69.5	75	72.25

GWT-LDA	82.76	85.33	84.1

GWT-KDCV (RBF)	81	82.50	81.75

GWT-KDCV (Cosine)	83	85	84.5

GWT-KDCV (RBF, low-energized)	88.5	91.5	90

GWT-KDCV (Cosine, low-energized)	92.5	95.75	94.1


Technique	Description	Metrics	Evidence of changes in trauma	Population

Time domain	Estimation of variability using statistics and measures of central tendency [3]	HRVi	↓ predicts mortality, ICH, adrenal insufficiency [11, 15, 19–22, 36]	ICU

Uncoupling	↑ reflects acidosis, coagulopathy, MOSF, AI, severe TBI, ↑ ICP, predicts mortality [6, 9, 12, 22]	ICU

SDNN	↓ predicts TBI, mortality, acidosis, LSI [16, 23]	PrehospitalERICU

RMSSD	↓ reflects TBI, hemorrhage, mortality [23, 28, 47]	ERICU

Frequency domain	Calculation of power (amplitude) of contributing frequencies to an underlying signal [18]	TP	↓ reflects ↑ICP, TBI, prolonged neurologic recovery, need for LSI, mortality, brain death [10, 28, 43]	ICUOutpatient

LF	↓ reflects ↑ICP, TBI, hemorrhage, need for LSI, mortality, brain; ↑ reflects ↑CI, HR, MAP death [4, 10, 27, 28, 37, 43, 48, 49].	ERICU

HF	↓ reflects trauma, ↑ICP, need for LSI, hemorrhage, brain death, and mortality [10, 37, 43, 47, 50, 51]	Prehospital

LF/HF	↑ reflects ↑ICP, ↓CPP; ↓ reflects brain death, mortality, hemorrhage, ↓GCS, poor neurologic outcome [5, 7, 10, 27, 48, 51]	PrehospitalICU

Entropy	Measurement of overall disorder, randomness, or irregularity of a physiologic signal [18]	MSE	↓ predicts mortality [13, 35, 36, 45]	ICU

ApEn	↓ reflects trauma, burn, hemorrhage, brain death, and ↑ICP, MOSF, predicts mortality; ↑ reflects resuscitation [8, 14, 25, 29, 34, 37, 52]	Prehospital

SampEn	↓ reflects trauma, mortality, burn, and hemorrhage;↑ reflects resuscitation; predicts LSI [8, 25, 43]	Prehospital

FDCL	↓ reflects hemorrhage; ↑ reflects resuscitation;↓ predicts LSI [17]	Prehospital

FDDA	↓ reflects need for LSI, hemorrhage, mortality [8, 25, 43]	Prehospital

DFA	↓ reflects mortality; predicts LSI [8, 25, 43]	Prehospital

SOD	↑ reflects need for LSI, mortality [8, 25, 43]	Prehospital

StatAv	↓ reflects mortality [25]	Prehospital


	Weeks postinfection

	4	7	10

	Control rats	Infected rats	Control rats	Infected rats	Control rats	Infected rats

TAS mol/g tissue	110.6 ± 6.5	93.5 ± 7.3a	108.2 ± 6.9	91.4 ± 7.5a	112.5 ± 6.1	98.8 ± 7.7a


KEGG category	Distinct ECs	ECs found in the data (% abundance)	N° of matches

Energy metabolism	173	92 (53.5%)	3,857

Carbon fixation	25	21 (84%)	986

Methane metabolism	33	12 (36.4%)	202

Nitrogen metabolism	58	30 (51.7%)	739

Oxidative phosphorylation	17	09 (52.9%)	972

Photosynthesis	03	01 (33%)	168

Redutive carboxylate cycle (CO2 fixation)	13	13 (100%)	531

Sulfur metabolism	30	12 (40%)	267

Biodegradation of Xenobiotics	217	66 (30.4%)	2,495

DDT degradation	10	03 (30%)	74

1,2-Dichloroethane degradation	05	04 (80%)	85

1,4-Dichlorobenzene degradation	22	06 (27.3%)	74

2,4-Dichlorobenzoate degradation	29	03 (10.3%)	18

3-Chloroacrylic acid degradation	04	04 (100%)	185

Atrazine degradation	12	04 (33.3%)	24

Benzoate degradation via CoA ligation	45	23 (51%)	994

Benzoate degradation via hydroxylation	50	18 (36%)	158

Biphenyl degradation	13	03 (23.1%)	71

Caprolactam degradation	22	10 (45.5%)	131

Carbazole degradation	11	01 (9.1%)	03

Ethylbenzene degradation	09	03 (33.3%)	207

Fluorene degradation	13	03(23.1%)	64

Naphthalene and anthracene degradation	21	03 (14.3%)	188

Styrene degradation	21	09 (42.9%)	73

Tetrachloroethene degradation	07	01 (14.3%)	57

Toluene and xylene degradation	22	07 (31.8%)	32

γ-Hecachlorocyclohexane degradation	24	07 (29.2%)	57

Carbohydrate metabolism	576	284 (49.3%)	9,901

Aminosugars metabolism	41	25 (61%)	589

Ascorbate and aldarate metabolism	43	18 (41.9%)	367

Butanoate metabolism	53	34 (64.2%)	1,802

C5-Branched dibasic acid metabolism Fructose	17	03 (17.6%)	126

and mannose metabolism	66	28 (42.4%)	591

Galactose metabolism	37	19 (51.4%)	529

Glycolysis/Gluconeogenesis	42	29 (69%)	858

Glyoxylate and dicarboxylate metabolism	58	30 (51.7%)	676

Inositol metabolism	09	07 (77.8%)	90

Inositol phosphate metabolism	30	05 (16.4%)	34

Nucleotide sugars metabolism	34	18 (52.9%)	517

Pentose and glucuronate interconversions	56	27(48.2%)	229

Pentose phosphate pathway	39	31 (79.5%)	846

Propanoate metabolism	49	34 (69.4%)	1032

Pyruvate metabolism	65	39 (60%)	1,117

Starch and sucrose metabolism	73	33 (45.2%)	498


Name	Descriptions	Reference

Bacterial strains

E. coli BL21 (DE3)	F-, dcm, ompT, gal, lon, hsdSB (rB−, mB−), λ (DE3[lacI, lacUV5-T7 gene 1, ind1, sam7,nin5])	Lab stock

J3	E. coli BL21 (DE3) harboring rbcLS-pET30a + (M259T)	[15]

JB	E. coli BL21 (DE3) harboring both PBAD-his6-prkA-pACYC184 and rbcLS-pET30a + (M259T)	[15]

MZ	E. coli BL21 (DE3) Δzwf	[16]

MZL	MZ, Δldh	This study

MZLF	MZL, Δfrd	This study

MZLF1	MZLF harboring PBAD-his6-prkA-pACYC184	This study

MZLF3	MZLF harboring rbcLS-pET30a + (M259T)	This study

MZLFB	MZLF harboring both PBAD-his6-prkA-pACYC184 and rbcLS-pET30a + (M259T)	This study

Plasmids

pKD46	araC, bla, oriR101, repA101 (Ts), araC-ParaB-γ-β-exo (encode λ Red recombinases), temperature-conditional replicon	[30]

pkD13	bla, FRT-kan-FRT	[30]

pCP20	FLP+, λ cI857+,λ PR Pepts, bla, catF	[31]

PBAD-his6-prkA-pA CYC184	Recombinant plasmid carries prkA gene (derived from Synechococcus PCC7492) for the overexpresion of phosphoribulokinase (PrkA) under the control of PBAD	[13]

rbcLS-pET30a + (M259T)	Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T) under the control of PT7	[13]

rbcLS-pET30a + (M259T, K198G)	Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T and K198G) under the control of PT7	This study

rbcLS-pET30a + (M259T, K198G, D200G, E201G)	Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, D200G, and E201G) under the control of PT7	This study

rbcLS-pET30a + (M259T, K198G, K172G)	Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K172G) under the control of PT7	This study

rbcLS-pET30a + (M259T, K198G, K331G)	Recombinant plasmid carries engineered rbcLS gene (originated from Synechococcus PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K331G) under the control of PT7	This study


	GPA score	SIR score	BSBM score

	0	0.5	1	0	1	2	0	1

Age	≥60	51-59	≤50	≥60	51-59	≤50	NA

KPS	<70	70-80	90-100	≤50	60-70	>70	50-70	80-100

Control of primary cancer	NA	PD	PR-SD	CR-NED	No	Yes

Volume of the largest BM (cc)	NA	>13	5-13	<5	NA

No. of BM	>3	2-3	1	≥3	2	1	NA

EC metastasis	(+)		(−)	NA	(+)	(−)


Screening tool	Positive result	Sensitivity	Specificity	Study Populations

 	 	(95% CI)	(95% CI)

AUDIT-C	≥ 4 (men)	86 (80-92) men	89 (85-93) men	Primary care [24]

(3 items)*	≥ 3 (women)	73 (66-79) women	91 (89-93) women

Quantity-Frequency	Exceeding recommended	88 (83-94) men	84 (80-89) men	Primary care [24]

(3 items)*	drinking limits	68 (61-75) women	91 (89-93) women

Heavy-drinking day	Any heavy days (≥ 4 drinks women, ≥ 5 drinks men)	83 (71-90) men	72 (61-81) men	Primary care [27]

past year (1 item)	 	81 (64-91) women	84 (76-89) women


Treatment	ctb	csb	del	r	cf	ra	Total aberrationsa

Solvent control : Tween-80 (1%)	-	1	-	6	6	-	13 ± 0.58

Methyl methansulfonate (MMS)	-	16	-	17	12	-	44 ± 3.06

TOF enriched extract	-	3	-	3	3	-	9 ± 1.53

Aqueous extract	-	4	-	4	2	-	10 ± 0.62

Methanolic extract	-	-	-	3	11	-	14 ± 0,58

Solvent control : Tween-80 (5%)	-	-	-	10	7	-	17 ± 1.15

Ethyl acetate extract	-	2	-	12	5	-	19 ± 1.53


Ingredient	Control Cream	Test Cream

Xyliance	4%	4%

Kendi oil	0.5%	0.5%

Phenoxyethanol	0.5%	0.5%

Aqua	QS	QS

Rhodosorus marinus extract/Dexamethasone		1% or 3%/0.2%


Parameters	Respondents	Mbarali district (%)	Momba district (%)	p value

Age of household head (years)

 15-30	120	1.7	11.7	0.013

 31-45	120	52.5	45

 46-60	120	35	29.2

 >60	120	10.8	14.2

Experience of keeping cattle (years)

 <5	120	1.7	11.7	0.005

 5-10	120	35	37.5

 >10	120	63.3	50.8

Level of education of the household head

 No formal education	120	0.8	25	<0.0001

 Primary education	120	80	65

 Secondary education	120	19.2	9.2

 College education	120	0	0.8

Land owned by the household

 <5 acres	120	3.3	15.8	0.01

 5-10 acres	120	36.7	34.2

 11-50 acres	120	57.5	46.7

 >50 acres	120	2.5	3.3

Number of cattle raised by the household

 <10 cattle	120	3.3	34.2	<0.0001

 10-50 cattle	120	68.3	59.2

 >50 cattle	120	28.3	6.7


	Delusions of guilt	Delusions of grandiosity	Persecutory delusions	Somatic delusions	None of these delusional types

Schizophrenia	2 (1.7%)	7 (6.0%)	33 (28.4%)	7 (6.0%)	76 (75.5%)

Delusional disorder	0	1 (2.4%)	21 (50.0%)	3 (7.1%)	19 (45.2%)

Schizoaffective disorder, manic type	0	2 (22.2)	1 (11.1%)	0	6 (66.7%)

Schizoaffective disorder, mixed type	0	0	1 (14.3%)	1 (14.3%)	5 (71.4%)

Schizoaffective disorder, depressive type	2 (8.3%)	0	4 (16.7%)	0	18 (75.0%)

Bipolar I disorder, current episode manic	0	16 (21.6)	7 (9.5%)	1 (1.4%)	54 (73.0%)

Bipolar I disorder, current episode mixed	1 (9.1%)	1 (9.1%)	3 (27.3%)	1 (9.1%)	7 (63.6%)

Bipolar disorder, current episode depressed with psychotic features	6 (42.9%)	0	6 (42.9%)	4 (28.6%)	3 (21.4%)

Major depressive disorder with psychotic features	24 (47.1%)	0	3 (5.9%)	6 (11.8%)	22 (43.1%)

Between-group differences	MDD > all other groups except BD and BM (p < 0.001)BD > all other groups except BM and SAD (p < 0.01)	M > MDD and SC (p < 0.001)SAMA > MDD (p < 0.05)	SC (p < 0.05), DD (p < 0.01), and BD (p < 0.05) > MDDDD (p < 0.01) and BD (p < 0.05) > M	BD > M (p < 0.01)


Item	Common themes	Groups	Quotes

Description and causes of fatigue.	Overwhelming physical tiredness with consequences on difficulties to move	Common in all groups: RA, AxSpA and fibromyalgia	I feel that my body is broken and every movement is as if I was moving a mountain

The need to rest more	RA and fibromyalgia	In the morning when I see my kids, I already feel tired and I even feel that I did not want to wake up

A sense of freezing of the body	AxSpA	When I have fatigue, my body is wooden and I move with difficulty

A toxin in the body	RA and AxSpA	It is toxic in my body, everything becomes difficult

Fatigue and pain	Close association between fatigue and pain	Common in all groups: RA, AxSpA and fibromyalgia

Daily patterns of fatigue	Fatigue is more in the morning	AxSpA	When I get up I feel that I am very tired and I wait for one hour to be able to move

Fatigue is more in the evening	RA, AxSpA	At the end of the day when I have finished my tasks I feel that my body is broken

No special daily patterns	Fibromyalgia

Consequences of fatigue	Fatigue affected physical activity to the extent that participants did their work only minimally	Common in all groups: RA, AxSpA and fibromyalgia	I do important things only

Social activities became limited to the close family and to very important occasions.	RA and fibromyalgia (female only)	I go to weddings and condolence gatherings only, because of my fatigue

Fatigue affected leisure activities markedly	RA and fibromyalgia	I forget what leisure means

	A difficulty in reaching the place of work	Common in all groups: RA, AxSpA and fibromyalgia	I can hardly walk to my work though it is only about 30 min

	Women told their husbands to marry again	RA and fibromyalgia	I asked my husband to marry again, he needs a healthy woman and I am too tired

	A decrease in male sexual activity	AxSpA	I get fatigued easily and this is a problem for my sexual life

Coping strategies	Dividing big tasks into smaller multiple tasks	Common in all groups: RA, AxSpA and fibromyalgia

	Getting help from family members	RA	My mother and sisters help me to complete my daily tasks


Cluster	TRANSFAC Annotations

A	V$POU3F2_02

	V$ISRE_01: interferon-stimulated response element

	V$DEAF1_01

	V$E2F1_Q3_01

	V$MAZR_01: MAZ related factor

	V$KROX_Q6

	V$E2F1DP1_01: E2F-1:DP-1 heterodimer

	V$HNF1_Q6

	V$E2F_Q3_01

	V$E2F1_Q6: E2F-1

Cluster	Common GO Parent Node	Gene Ontology	GO Level	GO Name

B	signal transduction [4] GO:0007165	GO:0007264	6	small GTPase mediated signal transduction

		GO:0007165	4	signal transduction

		GO:0007242	5	intracellular signaling cascade

C	programmed cell death [5] GO:0012501	GO:0006917	8	induction of apoptosis

		GO:0012502	7	induction of programmed cell death

		GO:0043068	6	positive regulation of programmed cell death

		GO:0043065	7	positive regulation of apoptosis

		GO:0050794	3*	regulation of cellular process

		GO:0016265	3*	death

		GO:0008219	4*	cell death

		GO:0012501	5	programmed cell death

		GO:0006915	6	apoptosis

		GO:0043067	5	regulation of programmed cell death

		GO:0042981	6	regulation of apoptosis

D	response to stress [4] GO:0006950	GO:0006950	4	response to stress

E	macromolecule metabolic process [4] GO:0043170	GO:0006493	9	O-linked glycosylation

		GO:0043170	4	macromolecule metabolism

		GO:0044260	5	cellular macromolecule metabolism

		GO:0019222	4*	regulation of metabolism

F	transcription [6] GO:0006350	GO:0006350	6	transcription

		GO:0045449	6	regulation of transcription

		GO:0019219	5*	regulation of nucleo-base, -side, -tide and nucleic acid metabolism

		GO:0006355	7	regulation of transcription, DNA-dependent

		GO:0006351	7	transcription, DNA-dependent

G	cell cycle process [6] GO:0022402	GO:0000082	7	G1/S transition of mitotic cell cycle

		GO:0000132	11	mitotic spindle orientation

H	mevalonate transport [8] GO:0015728	GO:0015728	8	mevalonate transport


Neonate causes	Level 1	Level 2A	Level 2B

Birth asphyxia	461	0	0

Congenital malformation	250	0	0

Meningitis (serious infection)	6	0	0

Pneumonia (serious infection)	84	5	0

Preterm delivery (<33 weeks gestational age [GA]) without respiratory distress syndrome (RDS)	353	0	0

Preterm delivery (with or without RDS) and sepsis	75	1	0

Preterm delivery (without RDS) and birth asphyxia	89	0	0

Preterm delivery (without RDS) and sepsis and birth asphyxia	34	0	0

Respiratory distress syndrome (33-36 weeks GA)	13	0	0

Respiratory distress syndrome (<33 weeks GA)	97	0	0

Sepsis (serious infection)	127	1	0

Sepsis with local bacterial infection	32	1	0

Stillbirth	1,001	1	0

Tetanus	4	0	0


Clinical group	Age at diagnosis(mean and range)	Preexisting cardiovascular disease/hypertension	Preexisting type II diabetes	Smoker/exsmoker 	Mean follow-up time posttreatment (years)	Mean time to onset of Grade 3 proctitis (range)

Control	69 (60–77)	8/20	3/20	8/20	6	N/A

Radiosensitive	73 (68–76)	6/10	1/10	4/10	7	21 months(9–41 months)


Group	Protein length (aa)	Exon number	Exon length (nt)

Mean	Median	K	Mean	Median	K	Mean	Median	K

Alveolata	535	364	e	3.6	2	i	449	161	h

Amoebozoa	463	351	f	3.1	2	j	448	192	f

Chlorophyta	490	369	e	5.4	3	g	270	139	j

Choanoflagellida	648	459	b	8.2	6	b	237	113	m

Cryptophyta	435	316	h	6.5	5	c	199	82	n

Excavata	471	334	g	1.1	1	m	1330	935	a

Fungi	462	381	d	3.3	2	k	421	195	e

Haptophyta	367	294	i	3.7	3	h	295	164	g

Ichthyosporea	637	494	a	4.8	4	d	398	152	i

Metazoa	595	439	c	10.1	7	a	176	126	l

Nucleariida	690	499	a	4.8	4	e	429	216	c

Rhodophyta	411	334	g	1.9	1	n	665	330	b

Stramenopila	467	356	f	3.5	2	l	399	196	d

Streptophyta	436	363	f	5.7	4	f	230	128	k


Model	Bayes factor

40° Head orientation

Body orientation + hemifield	1

All other models	>100

20° Head orientation

Body orientation + hemifield	1

Body orientation * hemifield	22

All other models	>100


 	UEBMI	URBMI

 	Insured	Uninsured	Insured	Uninsured

Dependent variable

 Outpatient visit rate (%)	13.02	7.69	12.74	7.93

 Inpatient visit rate (%)	6.11	5.52	4.68	2.99

Need variables

 Female	47.3	50.5	58.5	58.5

 45-59	34.1	36.7	23.5	23.0

 60+	16.8	15.0	16.4	16.5

 Health status	79.2	80.2	81.5	81.9

 Illness	12.9	12.8	12.3	10.2

 Chronic disease	16.6	17.0	18.7	16.0

Control variables

 Annual personal expenditure	7192	7322	6840	7026

 Married	82.6	81.9	63.5	61.5

 Other married status	8.5	8.3	10.8	11.6

 Commercial health insurance	5.1	4.3	4.7	4.0

 Household population	3.5	3.6	3.5	3.5

 Distance to the nearest health institution	10.0	8.8	9.8	9.5


Classification	 	BMI (kg/m2)

Underweight (A)	Thinness class III	< 16.00

 	Thinness class II	16.00-16.99

 	Thinness class I	17.00-18.49

Normal (B)	Eutrophia	18.50-22.99

 	 	23.00-24.99

Overweight (C)	Pre-obesity	25.00-27.49

 	 	27.50-29.99

Obesity (D)	Obesity class I	30.00-32.49

 	 	32.50-34.99

 	Obesity class II	35.00-37.49

 	 	38.00-39.99

 	Obesity class III	≥ 40.00


CATEGORY	ISSUES	EXAMPLES

Human resources	Teachers	“Some people hate school because teachers are terrible, they are not teaching and do not know how to teach.”

Managers	“Managers do not care about our quality of life.”

Moral abuse	Residents and teachers	“There are arrogant teachers.”

Demandings	Personal, familiar, institutional, and social	“The least I can do is to push myself as much as I can do.”

“Pressure in the medical program is big.”

Eating habits	Inadequate eating habits	“I learned from a resident to put lots of sugar in my coffee to curb the hunger.”

Financial resources	Financial dependence	“You cannot work during the program; I feel bad for being dependent on my parents.”

Lack of care with own health	Students adopt unhealthy life	“You see many medical students getting sick, being down, neglecting one's own body, unable to reflect on these things.”

Sleep	Sleep privacy	“I want, I need to sleep. I cannot do more shifts and study.”

Time	Demands of the program	“I think excessive workload decreases quality of life. You have class every day and then you have to study but you also have many other things in your life.”

 	 	“In the program there’s a lack of quality of life. Lack of time to lose, to think about life, plans, dreams.”


De Qi Characteristics	Acupuncture		Mock laser

C 1	C2	De Qi Characteristics	C 1	C 2

Dull pain	.857		Heaviness	.914

Sharp pain	.823		Aching	.887

Throbbing	.770		Deep pressure	.857

Cold	.761		Soreness	.836

Tingling	.728		Fullness/ Distension	.766

Warmth	.697		Warmth	.727

Aching	.575		Tingling	.668

Fullness/ Distension		−.912	Sharp pain	.614

Soreness		−.899	Numbness	.511

Deep pressure		−.847	Throbbing		.889

Heaviness		−.781	Cold		.847

Numbness		−.664	Dull pain		.598


	Body weight	BMI	WC	VFA	SFA	FPG	2-h PG	HOMA-IR	OGIS	HOMA-β	II

Essential AAs

 Histidine	—	—	—	—	—	—	—	—	—	—	—

 Isoleucine	0.413	0.305	0.345	0.332	—	—	—	—	—	—	—

 Leucine	0.488	0.300	0.361	0.413	—	—	—	—	—	—	—

 Lysine	0.307	—	0.290	—	—	0.236	—	—	−0.257	—	—

 Methionine	—	—	—	—	—	—	—	—	—	—	—

 Phenylalanine	0.276	—	—	—	—	—	—	—	—	—	—

 Threonine	—	—	—	—	—	—	—	—	—	—	—

 Tryptophan	—	—	—	0.289	—	—	—	—	—	—	—

 Valine	0.539	0.387	0.482	0.397	—	0.254	—	0.219	−0.297	—	—

Nonessential AAs										—

 Alanine	—	—	—	—	—	—	—	—	—	—	—

 Arginine	—	—	—	—	—	—	—	—	—	—	—

 Asparagine	—	—	—	—	—	—	—	—	—	—	—

 α-ABA	—	—	—	—	—	—	—	—	—	—	—

 Citrulline	—	—	−0.242	—	−0.395	—	—	−0.291	—	−0.375	—

 Cystine	0.276	—	0.285	—	—	0.236	—	—	—	—	—

 Glutamate	0.548	0.443	0.528	0.568	—	0.439	0.302	0.292	−0.458	—	—

 Glutamine	−0.241	−0.289	−0.326	−0.272	−0.396	—	−0.220	−0.398	—	−0.311	—

 Glycine	−0.333	−0.418	−0.426	−0.426	−0.294	—	−0.247	−0.317	0.303	−0.231	—

 Ornithine	—	—	—	—	—	—	—	—	—	—	—

 Proline	—	—	—	—	—	—	—	—	—	—	—

 Serine	−0.368	−0.273	−0.351	−0.379	—	—	—	—	0.258	—	—

 Taurine	—	—	—	—	—	−0.240	—	—	—	—	—

 Tyrosine	0.335	—	0.314	0.252	—	0.269	—	—	−0.327	—	—


Characteristics	2005-2006	2006-2007	2007-2008	2008-2009

No. of programs enrolledin ILC	23	63	80	87

No. of ILC registrants	5596	6920	6136	10,327

Total no. of participantscompleting CKD module	560	1322	1435	1686

Population included in currentstudy*

No. of programs	23	61	76	87

No. of participants (%)	509	1233	1351	1609

PGY-1	161 (32)	466 (36)	503 (37)	698 (43)

PGY-2	176 (34)	399 (32)	483 (36)	482 (30)

PGY-3	172 (34)	388 (32)	365 (27)	429 (27)

Programs affiliated with renalfellowship, n (%)	11 (48)	27 (43)	33 (43)	38 (44)

Programs by regional ESKDrate, n (%)

Located in region withhighest ESKD rate	6 (26)	26 (43)	26 (34)	27 (31)

Located in region withlowest ESKD rate	1 (4)	6 (10)	4 (5)	9 (10)

Mean pre-test score,% (SD)	45.1 (18.2)	49.3 (19.3)	57.0 (20.2)	55.2 (19.8)


Gene (species)	Sequence 5′→3′

CCL-2 (Homo sapiens) (NM 002982.3)	Fw: TCA GCC AGA TGC AAT CAA TG

Rev: ACA CTT GCT GCT GGT GAT TCT

IL-1β (Homo sapiens) (NM 000576.2)	Fw: AGC CAA TCT TCA TTG CTC AAG T

Rev: AGT CAT CCT CAT TGC CAC TGT

IL-6 (Homo sapiens) (NM 000600.3)	Fw: CAG CCC TGA GAA AGG AGA CAT

Rev: AGC CAT CTT TGG AAG GTT CA

IFN-γ (Homo sapiens) (NM 000619.2)	Fw: TGG AAA GAG GAG AGT GAC AGA A

Rev: TTG GAT GCT CTG GTC ATC TTT A

TNF-α (Homo sapiens) (NM 000594.3)	Fw: CTC TCT CCC CTG GAA AGG AC

Rev: ATC ACT CCA AAG TGC AGC AG

IL- 10 (Homo sapiens) (NM 000572.2)	Fw: TGTCATCGATTTCTTCCCTGT

Rev: TGC CTT TCT CTT GGA GCT TAT T

RPL-27(Homo sapiens) (NM 000988.3)	Fw: CCG AAA TGG GCA AGT TCA T

Rev: CCA TCA TCA ATG TTC TTC ACG A

IL-8 (Homo sapiens) (NM 000584.3)	Fw: AGC TCT GTG TGA AGG TGA T

Rev: TTT GGG GTG GAA AGG TTT G

ZAG (Homo sapiens) (NM 001185.3)	Fw: CCA GGA GAA CCA AGA TGG TC

Rev: CTG CTT CCA ATC CTC CAT TC

PIF (Homo sapiens) (NM 005268627.1)	Fw: AGG AAG CAG AGA TCC AGC CT

Rev: GGC TCC TTT ACC CAC GCT TT

HPRT1(Homo sapiens) (NM 000194.2)	Fw: TGG CGT CGT GAT TAG TGA TG

Rev: CTT GAG CAC ACA GAG GGC TA


Tool	URL	References

BLAST	http://blast.ncbi.nlm.nih.gov/Blast.cgi	(18)

MAFFT MSA	http://www.ebi.ac.uk/Tools/msa/mafft/	(19)

NetMHCpan	http://www.cbs.dtu.dk/services/NetMHCpan/	(20)

NetMHCIIpan	http://www.cbs.dtu.dk/services/NetMHCIIpan/	(21)

Search tool for HPV antigens	http://cvc.dfci.harvard.edu/hpv/HTML/search.php

Search tool for T cell epitope/HLA ligand	http://cvc.dfci.harvard.edu/hpv/HTML/searchT.php

Blast HPVdb	http://cvc.dfci.harvard.edu/hpv/HTML/blast.php

MSA of HPV sequences	http://cvc.dfci.harvard.edu/hpv/HTML/alignment.php

Sequence variability analysis tool	http://cvc.dfci.harvard.edu/hpv/HTML/varability.php	(14)

T cell epitope/HLA ligand visualization tool	http://cvc.dfci.harvard.edu/hpv/HTML/viewEpitope.php

Classification of the viruses based on cancer risk	http://cvc.dfci.harvard.edu/hpv/HTML/classification.php

HLA binding prediction tool	Embedded in each antigen entry table

T cell epitope/HLA ligand conservation analysis tool	Embedded in each experimentally validated T cell epitope/HLA entry table; also embedded in each HLA binding prediction result page.


Gene	Low n-3 LC-PUFA HL/LL	High n-3 LC-PUFA HH/LH

 	Microarray	RT-qPCR	Microarray	RT-qPCR

LC-PUFA biosynthesis

Δ5fad	 	−1.03	 	1.35

Δ6fad	 	1.04	 	−1.32

elovl2	−1.28 to −1.41	−1.51	−1.82 to −1.97	−1.62

Cholesterol biosynthesis

ipi	 	−3.95	 	1.31

mev	 	−1.40	 	1.14

7dchr	 	−1.01	 	1.09

srebp2	 	−2.09	 	1.29

Lipid transport and lipoprotein metabolism

lrp1	 	−1.82	 	−1.08

apoA4a	 	−1.37	 	−0.95

apoA4b	 	−2.43	 	−1.80

lpl	 	−1.18	 	−1.05

Immune response

cfh	−1.33 to −1.56	−1.24	−1.56 to −1.69	−1.31

trim25	−5.64	−2.09	−4.34	−2.33

lect2	3.16	1.23	4.86	4.84


Position 1	NY-3356 Genome	IC Plasmids	Amino Acid Change	Location

1285	T	C	Silent	E

3840	T	C	Silent	NS2A

70292	G	A	Silent	NS4B

7826	T	C	V➔A	NS5

8067	G	A	Silent	NS5

9123	C	T	Silent	NS5

10613	C	T	Silent	3’ UTR

10783	C	T	Silent	3’ UTR


Bioprosthesis type	Manufacturer	Valve diameters (mm)

Trifecta	St. Jude Medical, Minneapolis, USA	19 to 29

Mitroflow	Sorin Group, Saluggia, Italy	19 to 29

Carpentier-Edwards Magna Ease	Edwards Lifesciences, Irvine, USA	19 to 29


Process Modes	Position (cm)	Velocity (cm/s)	Attitude (°)

North	East	Down	North	East	Down	Roll	Pitch	Heading

IC-PPP	6.6	8.9	6.6	6.7	7.2	8.3	-	-	-

IC-PPP/INS	3.2	4.8	5.5	1.0	1.1	0.8	0.021	0.026	0.092

LC-PPP/INS	4.2	6.5	6.1	1.2	1.1	0.9	0.022	0.027	0.095


Underlying medical condition	All	<5 years	5 - 59 years	60+ years	Pregnant or postpartum

N = 183	n = 29	n = 134	n = 20	n = 27

Cases	%	Cases	%	Cases	%	Cases	%	Cases	%

Obesity	27	15 %	0	0 %	23	17 %	4	21 %	2	7 %

Diabetes Mellitus	23	13 %	0	0 %	16	12 %	7	37 %	2	7 %

Asthma	20	11 %	2	7 %	15	11 %	3	16 %	5	18 %

Other chronic metabolic disease	15	8 %	1	3 %	9	7 %	5	26 %	0	0 %

Immunosuppression	15	8 %	2	7 %	10	7 %	3	16 %	1	4 %

Chronic lung disease	10	5 %	0	0 %	8	6 %	2	11 %	2	7 %

Chronic seizures	11	6 %	3	10 %	8	6 %	0	0 %	0	0 %

Chronic cardiac disease	7	4 %	1	3 %	5	4 %	1	5 %	3	11 %

Cerebral palsy	7	4 %	1	3 %	6	4 %	0	0 %	0	0 %

At least one chronic condition	112	61 %	11	38 %	82	61 %	19	100 %	14	50 %


 	Korea	Japan

Expenditures on health by type of funding (%)

GG/SS/POP/PI	11/46/37/6	9/73/15/2

Share of hospital inpatient expenditures for MSD (%)	9	6

Health care system

Out-of-pocket healthcare expenditures as a share of total household consumption (%)	4.6	2.2

Sickness leave	No	66.7% of average daily basic wage up to 18 months

Share of WMSD in workers’ compensation (%)

WMSD/total compensated diseases	71.5	66.6

WMSD/total compensated injury and diseases	5.8	4.3


Parameter	Cirrhosis	Controls

Bilirubin (total, mg/dL)	1.44 ± 0.95	0.89 ± 0.24

Albumin (gm/dL)	4.0 ± 0.5	3.7 ± 0.9

PT (secs)	14.4 ± 1.8	11.4 ± 0.8

Ascites	2/26	0/13

Enceplalopathy	0/26	0/13


Symbol	Chr	UCSC annotated features	CpG island	Δ β-value	Bootstrap 95% CI

OBFC2B	12	Promoter associated	Shore	0.386	(0.227, 0.551)

GPR75; LOC100302652	2	5′UTR; 1st Exon; Enhancer	Island	0.349	(0.184, 0.515)

AIRE	21	Within 100 bp of TSS	Island	0.267	(0.094, 0.444)

MIMT1; PEG3;ZIM2	19	Within 500 bp of TSS; 5′UTR; 5′UTR	Island	0.207	(0.088, 0.332)

CIRBP; C19orf24	19	Body; Within 1000 bp of TSS	Island	0.176	(0.097, 0.256)

SMG6; SRR	17	Within 500 bp of TSS; 5′UTR	Shore	0.125	(0.039, 0.214)

GPR12	13	5′UTR	Island	-0.095	(-0.161, -0.030)


Rab	Determination on WPBs	Method	siRNA effect on VWF release	Comment	Reference

Rab27a	Endogenous expression and overexpression	Western blot, RT-PCR, and IF	Increase or decrease	–	26,34,47,50

Rab27b	Overexpression	RT-PCR	Decrease	Level of expression very low	47

Rab3A	Overexpression	RT-PCR	Decrease	–	47

Rab3B	Endogenous expression and overexpression	Western blot, RT-PCR, and IF	No effect	–	47,50

Rab3D	Endogenous expression and overexpression	Western blot, RT-PCR, and IF	Decrease or no effect	Endogenous Rab3D weakly detectable in 5% of cells	47,50,52

Rab15	Overexpression	RT-PCR	Decrease	–	47

Rab33a	Overexpression	RT-PCR	No effect	–	47

Rab37	Overexpression	RT-PCR	No effect	Low expression (cycle time 39.74)	47


	Odds ratio	95 % C.I. for odds ratio	P value

		Lower	Upper

External environment

Area of residence

Rural	1

Urban	1.364	1.081	1.721	0.009

Education

Non	1

Primary	1.666	1.297	2.141	0.001

Secondary +	1.929	1.380	2.697	0.001

Adult education	1.191	.688	2.063	0.533

Wealth index

Wealth index(score)	2.293	1.988	2.644	0.001

Parity

Parity >2	1

Parity 1-2	2.222	1.786	2.765	0.001

Enabling factors

Ante natal care

No	1

Yes	3.342	2.306	4.844	0.001

Need factors

Complications during pregnancy

No/Non-serious complication	1

Serious complication	1.606	1.319	1.957	0.001


Gene	Sequence

GK	forward 5′-TTGAGACCCGTTTCGTGTCA – 3′

	reverse 5′-AGGGTCGAAGCCCCAGAGT -3′

L-PK	forward 5′-TGATGATTGGACGCTGCAA – 3′

	reverse 5′-GAGTTGGTCGAGCCTTAGTGATC – 3′

HK2	forward 5′-AACCGAACAAGCTGGTGTAC-3′

	reverse 5′-TGCACACATCTATAGGTGGC-3′

ACC	forward 5′-CAACGCCTTCACACCACCTT -3′

	reverse 5′-AGCCCATTACTTCATCAAAGATCCT -3′

FAS	forward 5′-TGCTCCCAGCTGCAG -3′

	reverse 5′-GCCCGGTAGCTCTGGGTGTA -3′

ACOX1	forward 5′-AAGAAATCCCCACTGAACAAAACA -3′

	reverse 5′-CCCAGGGAAACTTCAAAGCTT -3′

CPT1a	forward 5′-ATATCAAGGACAGCAGGCACAT -3′

	reverse 5′-CTCAGCAGCCTCCCATGCT -3′

CPT1 b	forward 5′-CAGCCATGCCACCAAGATC -3′

	reverse 5′-CTTGGGCAGTGATGTTTGGA -3′

CD36	forward 5′-CAGCCTCCTTTCCACCTTTTG-3′

	reverse 5′-AAGGCGTTGGCTGGAAGAA-3′

PGC1α	forward 5′-ATACCGCAAAGAGCACGAGAAG-3′

	reverse 5′-CTCAAGAGCAGCGAAAGCGTCACAG-3′

PPARα	forward 5′-GGGATGAAGAGGGCTGAGC-3′

	reverse 5′-TGATTAACATTGGGCCGGTT-3′

BCAT2	forward 5′-GGCGGACCCTTCATTCGT-3′

	reverse 5′-TTCCCCCCCAACTTGCA-3′

BCKDHα	forward 5′-CCAGGGTTGGTGGGATGAG-3′

	reverse 5′-GGCTTCCATGACCTTCTTTCG-3′

UBE2B	forward 5′-AACGCAGTTATATTTGGACCAGAAG-3′

	reverse 5′-ACGGTTGGTGGTTTATTTGGAT-3′

CAD	forward 5′-CGCAGTGTTTCACAGTCGTCTT-3′

	reverse 5′-TGGACTTGTCACTGTTGTACTTATGG-3′

CCK	forward 5′-CAGGTCCGCAAAGCTCCTT3′

	reverse 5′-TCCAGGCTCTGCAGGTTCTT-3′

PYY	forward 5′-CGGCAGCGGTATGGAAAA-3′

	reverse 5′-TGTGAAGAGCAGTTTGGAGAACA-3′

GLP-1	forward 5′-CTCCCGCCGTGCTCAA-3′

	reverse 5′-TTGTTCCGGTTCCTCTTGGT-3′

GIP	forward 5′-CTGCTGGTGCTCCTGTTCCT-3′

	reverse 5′-CATGGGATCGGAACTCAACCT-3′


Discipline	Number

Medical	11,323

Nurses and midwives	40,926

Dentists	3,176

Pharmacists	1,100

Other HCW	16,640

Administrative staff	34,533

Total	107,698


Key challenges	Solutions	Future implications

1) Identification of centres willing/able to participate in the study

• Identifying centres with interest/capacity to participate in research and the correct people to discuss participation with proved difficult via conventional means (unsolicited mail/email).• Limitations in dedicating time or resources to external research projects due to clinical workloads and lack of designated support staff were common reasons for non-participation cited by centres. Levels of remuneration provided to centres for participation in the study were considered insufficient by some centres.• Availability of NHS staff participating in research having completed Good Clinical Practice (GCP) training.	• The ZQOL study was accepted into the National Institute for Health Research Clinical Research Network (NIHR CRN) portfolio. NIHR were able to offer wide range of support services including:o Access to existing networks of centres with interests in participating in research.o Provision of support to centres interesting in participating in research.o Exploring centre eligibility for additional remuneration for participation in NIHR CRN-approved studies.o Delivering GCP training to centres interesting in participating in studies.	• Experiences indicate the need for greater links between commissioners of research and primary/secondary care centres.• A refocusing of targets for primary care centres, to provide staff with opportunities and incentives for partaking in research is needed.• Current R&D approval process makes no concessions for non-interventional research. R&D requirements should be proportionate to the risks associated with patient participation in such studies.

2) Obtaining Ethics and Research & Development (R&D) Management Approval

• Information and documentation required to support R&D applications was a barrier to participation for a number of centres.• Significant variation in timelines for R&D approval at a local and regional level (i.e. England, Scotland, Wales & Northern Ireland) led to significant delays in the study.• R&D approval process requires that extensive tri-partite agreements between the study sponsor, co-ordinating CRO and R&D department be agreed and signed. However, there is no standard template available for such agreements.	• ZQOL study organisers implemented a number of practical solutions including:o Minimising the number of R&D approvals by seeking participation of clusters of centres in the same NHS trust.o Implemented a staged study roll-out such that R&D applications for key centres were prioritised and R&D applications could occur in parallel to patient recruitment.• NIHR CRN can also provide assistance:o As a NIHR-CRN portfolio adopted study, more likely to be considered for priority review by R&D depts.o NIHR CRN local research network teams are able to offer support and guidance to co-ordinating CROs throughout England.	• Current R&D approval process makes no concessions for non-interventional research. R&D requirements should be proportionate to the risks associated with patient participation in such studies.• A move to standardise R&D approval process across NHS trusts in England would reduce burden (and barriers) to research for study organisers and NHS staff interested in participating in research.

3) Recruitment of Study Participants

• Recruitment of HZ patients in primary care was slower than envisaged, a likely result of practical and organisational factors:o As an acute condition, HZ patients had to be recruited on initial presentation to physicians and did not allow searches of eligible participants via patient medical records.o At the time of the study there will only limited opportunities for notifications and reminders to be incorporated into electronic-record systems on presentation of incident cases.• Lack of unique identifiers or codes in electronic-record systems made it difficult to identify PHN patients for participation in the ZQOL study.	• To ensure that study recruitment quotas were met, additional centres were recruited for participation in the study and study timelines were extended.• NIHR CRN local research networks and the co-ordinating CRO were in regular contact with centre staff so to ensure to provide support where needed.	• Standardisation of medical record keeping and greater integration of record and monitoring systems would be to the benefit of facilitating real-world research.• Centres having systems in place to confirm the feasibility of recruitment numbers and having opportunity to work alongside study organisers could facilitate the development of study inclusion/exclusion criteria that are less restrictive to recruitment in real-world practice.


Case	Case summary	Examination type	Performing department	Allegation

1	Middle-aged female presented with calf pain. Ultrasound study reported to be negative. Patient had fatal pulmonary embolism. (2012 WL 1100657 [Ohio App. 7 Dist])	DVT	Radiology	Failure to perform complete examination

2	Teen-aged female presented with calf pain, palpitations and pre-syncope. EKG and chest x-ray normal. Patient died of massive pulmonary embolism. (2012 WL 1605709 (La.App. 5 Cir.), 11–1006 [La.App. 5 Cir. 5/8/12])	DVT	Not performed	Failure to perform

3	Teen-aged boy presented after motor vehicle collision. No abdominal imaging was performed. Patient was discharged and died that night at home with liver laceration and hemoperitoneum. (721 S.E.2d 238)	FAST	Not performed	Failure to perform

4	Adult female presented with abdominal pain. Right upper quadrant ultrasound scheduled next day. Positive for cholecystitis. Alleged delay in diagnosis prolonging hospitalization and causing complications. (2009 WL 2473514)	RUQ	Radiology	Failure to perform in a timely manner

5	Adolescent male 8 days status post knee arthroscopy presented with chest pain. Diagnosed with pleurisy and discharged. Patient subsequently died of bilateral pulmonary emboli. (2012 WL 5910796)	DVT	Not performed	Failure to perform


	ARDS patients	Age- and sex-matched reference values	P value

	Mean (SD)	Mean (SD)

EQ5D index at 6 months

Patients under 65	0.55 (0.37)	0.85 (0.06)	<0.001

Patients 65 and above	0.62 (0.37)	0.77 (0.02)	0.003

EQ5D at 12 months

Patients under 65	0.58 (0.35)	0.85 (0.06)	<0.001

Patients 65 and above	0.58 (0.38)	0.77 (0.02)	<0.001


	2016	2017	2018	2019

Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4

Protocol development	X

Training of research coordinators and physicians	X		X	X				X

Training of nurses for motivational counseling (yearly refresher training)		X			X				X

Obtaining informed consent, recruitment, and baseline interview				X	X	X	X

Auditing and site visit monitoring (every 2 weeks)				X	X	X	X	X	X	X	X	X	X	X	X

Trial supervision			X				X				X				X

Monthly Trial Management Committee meeting				X	X	X	X	X	X	X	X	X	X	X	X

Telephone follow-up by nurses (monthly until 3 months and then every 3 months)				X	X	X	X	X	X	X	X	X	X	X	X

Follow-up by clinical research coordinators (every 4 months by telephone; annually on site)					X	X	X	X	X	X	X	X	X	X	X

Data Safety and Monitoring Board meeting (every 6 months)		X			X		X		X		X		X		X

Trial Steering Committee Meeting (every 6 months)		X		X		X		X		X		X		X

Quality assessment			X			X			X			X			X

Progress or interim report						X

Data analysis														X	X

Manuscript writing														X	X

Final report														X	X


Diets	Intestine	Liver	Muscle	Brain

HD

LD				fabp7b

LND	fabp1b.1, fabp7b		fabp7a

LFD		fabp7a	fabp11a


 	Midwives	Child health nurses	Dental hygienists/dental nurses

 	Raising the topic with more than half or all pregnant women (%)	Wilcoxon Signed Rank Test	Raising the topic with more than half or all parents (%)	Wilcoxon Signed Rank Test	Raising the topic with more than half or all clients (%)	Wilcoxon Signed Rank Test

Topic	Pre	Post	p-value	Pre	Post	p-value	Pre	Post	p-value

Psychosocial health	73	86	.048	47	64	.053	-	-	-

Men’s violence against women/children	59	82	.010	11	36	.000	-	-	-

Tobacco	91	96	.581	72	89	.059	79	84	.690

Alcohol	91	96	.414	64	81	.109	0	21	.026

Drugs	91	82	.269	19	36	.004	-	-	-

Weight/BMI	76	86	.107	11	13	.169	5	26	.006

Discretionary foods	59	41	.790	23	43	.005	47	100	.001

Regular meals	59	46	.941	34	55	.035	53	100	.001

Beverage intake	-	-	-	-	-	-	63	100	.000

5 fruits and vegetables a day	67	82	.191	21	53	.000	32	100	.000

30 min daily physical activity	59	68	.129	11	36	.000	-	-	-

Parenthood/parent relationships	77	77	.623	64	83	.107	-	-	-

Tooth brushing/dental health (child)	-	-	-	55	89	.001	-	-	-

Weight/BMI (child)	-	-	-	77	81	.805	-	-	-

5 fruits and vegetables a day (child)	-	-	-	45	66	.002	-	-	-

Regular meals (child)	-	-	-	83	85	.907	-	-	-

Discretionary foods (child)	-	-	-	55	68	.026	-	-	-

Physical activity (child)	-	-	-	72	87	.068	-	-	-

Psychosocial health (child)	-	-	-	79	87	.337	-	-	-


	Severe (n = 12)	Mild (n = 5)

Birth Weight (g)	2500(2400–3000)a	3100 (3000–3600)	p = 0.04

Day of illness at hospital presentation	2.5 (2–3.5)	5 (5–5)	p = 0.02

Incubation period (days)	7 (7–10)	6 (5–7)	p = 0.04


Outcomes	Conventional periodn = 79 (%)	MALDI-TOF periodn = 75 (%)	P Value†

Time to pathogen identification (hours)	86.9 ± 30.4	62.5 ± 23.1	< 0.001

Time to effective therapy (hours)	27.8 ± 32.4	17.1 ± 25.7	0.031

30-day all-cause mortality	7 (8.9)	5 (6.7)	0.612

Time to microbiological clearance (days)	4.1 ± 3.0	3.4 ± 2.0	0.081

Length of ICU stay (days)	14.1 ± 26.0	11.7 ± 12.8	0.719

30-day Recurrence of same BSI	2 (2.5)	0 (0.0)	0.497


Mouse primers		Oligonucleotide sequences (5’−3’)

Aldh1a1-/-	Forward	TGAGCAAATCCTCCACAGCCCTGTTC

Reverse	CTGCTAAAGCGCATGCTCCAGACTG

Aldh1a3 flox	Forward	TCTCTGACCAGCTTTCCAACCTTCAG

Reverse	CTCAAACCAGCACCACCTCCATATTG

Sox9 flox	Forward	TCAGCAAGACTCTGGGCAAGCTCT

Reverse	CTCAAAATCTGAGCCACTCCCTC

Tyr-Cre, Pax6-α-Cre	Forward	CCTGGAAAATGCTTCTGTCCGT

Reverse	GTGTCCACATAGTCATTGGCAGAGTG

Sox9-Tg, Kdr-BAC-EGFP	Forward	AGCTGACCCTGAAGTTCATCTG

Reverse	GTCGTCCTTGAAGAAGATGGTG

Flt1-BAC-tdsRed	Forward	GCTGCAGGCGCGGAGAAGGGCTCTC

Reverse	CTTCACGTACACCTTGGAGC

IL2 (internal control)	Forward	GCCTAGAAGATGAACTTGGACCTCTG

Reverse	GTGGAAGGATTCACTTGCACAGTGAC

Human RPE primers

Sox9	Forward	CGTACCCGCACTTGCACAAC

Reverse	TCTCGCTCTCGTTCAGAAGTC

Vegfa	Forward	TGCCCGCTGCTGTCTAAT

Reverse	TCTCCGCTCTGAGCAAGG

β-actin	Forward	CCAACCGCGAGAAGATGA

Reverse	CCAGAGGCGTACAGGGATAG


Survey items	Overall (n=48)	Completely achieved ILP goals and objectives

‘No’ (n=25)	‘Yes’ (n=23)

ILP helpful in structuring ACE learning objectives (Rate 1–5), no. (%)

 1-3 ratings	12 (25 %)	10 (40 %)	2 (9 %)

 4-5 ratings	36 (75 %)	15 (60 %)	21 (91 %)

ILP helpful in organizing goals for career (Rate 1–5), no. (%)

 1-3 ratings	19 (40 %)	15 (60 %)	4 (17 %)

 4-5 ratings	29 (60 %)	10 (40 %)	19 (83 %)


Variable	HE group (n = 58)	Control group (n = 59)	P-value

Historical information

 Esophageal varices	60%	66%	0.518

 Variceal bleeding	21%	24%	0.693

 Variceal band ligation	24%	24%	0.952

Medications

 Non-selective beta blockers	36%	44%	0.386

 Narcotics	14%	8%	0.394

 Centrally acting medicationsa	41%	15%	0.002

 Diureticsb	88%	63%	0.002

Laboratory tests

 Na <135 mmol/L	69%	68%	0.892

 Creatinine > 1 mg/dL	31%	29%	0.793

CT scan findings

 Liver antero-posterior diameter ≤6 cm	91%	68%	0.001

 Liver cranio-caudal diameter ≤16 cm	69%	58%	0.203

 Spleen diameter ≥16 cm	47%	53%	0.517

 Nodular liver	86%	68%	0.018

 Caudate lobe hypertrophy	55%	64%	0.308

 Paraesophageal varices	67%	63%	0.608

 Splenorenal varices	72%	83%	0.166

 Umbilical vein recanalization	60%	58%	0.765

 Presence of ascites	55%	49%	0.515

 Portal vein diameter ≤12 mm	58%	28%	0.001

Duplex ultrasound findings

 Portal vein flow velocity <16 cm/s	26%	20%	0.475

 Hepatofugal flow	16%	7%	0.132

 Hepatic artery resistive index ≥0.75	33%	39%	0.527


Variable	n	%

Surgical approach

 Laparoscopic, completely closed	20	90

 Hand-assisted laparoscopic	1	4.5

 Lap converted to open	1	4.5

No. of metastases resected	45

 1	14	64

 2	3	14

 ≥ 3	5	23

Segment of liver resected

 Combined segment 2 and 3	2	9

 Segment 3	8	36

 Segment 5	2	9

 Segment 6	8	36

 Segment 7	1	4.5

 Segment 8	1	4.5

Size (cm) of tumor resected (mean/median (range))	3.4/3 (0.3-8)

Operative specifics (mean/median (range))

 Intraoperative blood loss (mL)	256/100 (50–1400)

 Operative time (minutes)	194/193 (90–305)

 Use of pringle	3	14

 Parenchymal transection with ultrasonic device	21	95

 Parenchymal transection with endovascular stapler	15	68

Duration of hospitalization (days) (mean/median (range))	4/3 (1–10)

Postoperative complication	3	14

 Bile leak	1	4.5

 Rapid atrial fibrillation	1	4.5

 Colitis	1	4.5


ORF Clusters features	MFL x MHP*	MFL x MHR*	MFL x MHP x MHR*

OCs 100% conserved	44	17	12

OCs Partially conserved	44	35	33

OCs Without conservation	29	62	-


Conceptualization	Description

Revolution	• Health’s increasing role in foreign policy is transformative of the health-foreign policy nexus• Health collapses the traditional distinction between high and low politics and creates a new political space in which health isan overriding normative value and the ultimate goal of foreign policy• Health is broadly conceived and encompasses the social determinants of health• Is consistent with health discourses that focus on health as a human right and the “health for all” ideal

Remediation	• Health’s rise as foreign policy issue reflects the continued persistence of the traditional hierarchy of foreign policy functions• Health has become another issue that needs to be addressed through traditional approaches to foreign policy, or as astrategic vehicle through which traditional foreign policy goals can be achieved• Foreign policy attention on health is focused when disease crises appear and fades when crises drop off the political spotlight•Provides the strongest explanation for why health has risen as a foreign policy issue

Regression	• Health’s integration into foreign policy is a regressive development – an indicator that health problems are getting worse• The increasing attention paid to health across the functions of foreign policy signifies the failure of public health efforts• Connecting health with the high politics of foreign policy threatens to tarnish long-standing associations of health withnormative values• Public health’s wish for health to become more politically prominent may have come true but in a way that threatens whatwas special about health in the first place


	EU	Australia	Japan	WHO	Canada	Korea, India, Singapore, Malaysia

Synonym	Biosimilars	Biosimilars	Follow-on Biologics	Similar Biotherapeutic Product	Subsequent Entry Biologic	Biosimilars

Scope	Mainly recombinant protein drugs	Recombinant protein drugs

Principles	• Generic approach is not appropriate for SEB.

• SEB should be similar to the reference biologic with respect to quality, safety and efficacy.

• Step-wise comparability approach: the reduction of non-clinical and clinical data required will only be considered after the similarity of the SEB and reference biologic is proven in terms of quality.

• Case by case approach for different classes of products.

• Pharmacovigilance is stressed.

Reference product	Authorized in the EU	Authorized in Japan	Authorized in a region with a well-established regulatory framework

Manufacture	• Same standards required by the national regulatory agency for originator products.

• Full chemistry and manufacture data package.

Physio-chemical	• Primary and higher-order structure.

• Post translational modifications.

Purity	• Process-related and product-related impurities.

Non clinical	• In-vitro such as cell-based assays and receptor-binding studies.

Stability	Accelerated degradation studies and studied under various stress conditions	Not necessary	Accelerated degradation studies and studied under various stress conditions

Pharmacokinetic study design & criteria	• Single dose, steady-state studies or repeated determinations of pharmacokinetics

• Cross over or parallel.

• Include absorption and elimination characteristics.

• Use the traditional 80-125% equivalence range.

PD	Pharmacodynamic (PD) markers should be selected and comparative PK/PD studies may be appropriate

Efficacy	Comparability margins should be pre-specified and justified	Observer or double-blinded. Equivalence or non-inferiority	Equivalence

Safety/pharmacovigilance	• Pre-licensing safety data and risk management plan. Post authorization safety and/or efficacy studies may be required.

• Adverse reactions must be reported.

• Same rules apply to reference biologic and SEB.

INN vs. new generic name	INN	Unique generic name	Suffix “BS” added to INN	INN with biological qualifier (proposed)	INN but will follow WHO guidance	INN

Extrapolation of indications	• Assessed on a case-by-case basis.

• At least one clinical study required in the most sensitive population measuring the clinical endpoints likely to show a difference.


Pharmacovigilance area of interest

Activity type	Adverse events	Counterfeit drugs	Drug quality assurance	PV NOS	N/A	Total

 Behaviour change communication		6 (85.7)	1 (14.3)			7 (2.4)

 Improve regulatory system	1 (3.1)	6 (18.8)	14 (53.1)	11 (34.4)		32 (11.1)

 Improving supply chain		1 (6.7)	7 (46.7)	7 (46.7)		15 (5.2)

 Laboratory supplies and training		6 (15.4)	27 (69.2)	6 (15.4)		39 (13.5)

 Operations research	2 (66.7)		1 (33.3)			3 (1.0)

 Surveillance	3 (8.3)	10 (27.8)	21 (58.3)	2 (5.6)		36 (12.5)

 Training/capacity building		1 (9.1)	6 (54.5)	4 (36.4)		11 (3.8)

 Pharmacovigilance NOS	2 (6.3)	1 (3.1)	23 (71.9)	6 (18.8)		32 (11.1)

 Pharmacovigilance NOS-unfunded			26 (100)			26 (9.0)

 Surveillance-not funded	5 (100)					5 (1.7)

 Context onlya					39 (100)	39 (13.5)

 Historical activityb		12 (17.4)	37 (53.6)	17 (24.6)	3 (4.4)	69 (24.0)

 Total	14 (4.9)	40 (13.9)	154 (53.5)	49 (17.0)	42 (14.6)


Schizophrenic Patient Variables	Values

Schizophrenia Severity	Severe/Other

Schizophrenia Heavy Alcohol Use	Yes/No

Schizophrenia Heavy Drug Use	Yes/No

Schizophrenia	Paranoid/Undiff

Schizophrenia Sudden Death	Yes/No

Schizophrenia Suicide	Yes/No

Schizophrenia Lifetime Antipsychotics >45,000	Yes/No

Schizophrenia Antichollnergic	Yes/No

Schizophrenia Antidepressants	Yes/No

Schizophrenia Stabilizer	Yes/No

Schizophrenia Lithium	Yes/No

Schizophrenia Valproate	Yes/No


Reads	Assembler	Contig	Scaffold	Transf	Untransf	Shared	Masked

Sim	allp	57	7	21	1	18	12

Sim	sga_m75	504	463	NA	NA	NA	NA

Sim	sga_m77	513	479	NA	NA	NA	NA

Sim	soap_K69	1481	698	255	451	137	44

Sim	soap_K71	1469	769	NA	NA	NA	NA

Bs-1	allp	66	9	35	0	23	15

Bs-1	sga_m75	899	711	NA	NA	NA	NA

Bs-1	sga_m77	871	687	NA	NA	NA	NA

Bs-1	soap_K69	1916	670	365	429	210	95

Bs-1	soap_K71	1909	692	NA	NA	NA	NA


Variable	Beclin 1 expression

All Cases	Low	High	p Value

HER2 expression in total cases(41)				0.008

Negative	26	21(80.8%)	5(19.2%)

Positive	15	6(40.0%)	9(60.0%)

HER2 expression in ER positive cases(25)				0.002

Negative	18	16(88.9%)	2(11.1%)

Positive	7	1(14.3%)	6(85.7%)

HER2 expression in ER negative cases(16)				1.000

Negative	8	5(62.5%)	3(37.5%)

Positive	8	5(62.5%)	3(37.5%)


Group of patients	Survivin positive	Survivin negative	Total

COX-2 positive	55	8	63

COX-2 negative	15	15	30

Total	70	23	93


Characteristic	Healthy volunteers	RA patients

	(N = 7)	(N = 10)

Age: mean (range)	56 (49–62)	63 (49–80)

Gender (% female)	43%	50%


Line	Number of Individuals	Duplication	Deletion	HeR	Aneuploid	TOTAL

ACSRsyn1	16	2	2	0	0	4

Bronowski	16	0	1	0	0	1

Daichousen (fuku)	16	0	0	1	1	2

Maris Haplona	48	1	8	0	1	10

Surpass 400	16	0	0	0	0	0

Svalof’s Gulle	16	1	0	0	1	2

Tribune	16	2	2	0	1	5

Topas	16	0	1	0	1	2

PAK85912	46	5	4	5	3	17

Zhongyou821	48	3	2	0	4	9

Rainbow	254	12	22	30	13	77


Item	 	Number	Percent	Adjusted OR*	95% CI

A smoke-free hospital would improve the quality of care the patient receives (Agree)	Admin**	90	82.6%	1.0

Physicians	223	83.8%	1.4	0.63	3.1

 	Nurses	227	90.4%	2.2	0.84	5.7

Smoke from someone else's cigarette is unhealthy for non-smokers (Agree)	Admin	97	89.8%	1.0

Physicians	260	97.7%	4.6	1.41	15.1

 	Nurses	245	97.2%	3.6	1.04	12.6

The smoking habits of health professionals influence others (Agree)	Admin	100	91.7%	1.0

Physicians	258	97.0%	3.0	0.93	10.0

 	Nurses	236	93.7%	1.7	0.51	5.9

Cessation programs should be offered to employees (Agree)	Admin	101	92.7%	1.0

Physicians	254	95.5%	6.8	1.68	27.3

 	Nurses	239	95.2%	2.2	0.60	7.7

A hospital should be a smoke-free environment (Agree)	Admin	105	97.2%	1.0

Physicians	256	96.2%	1.2	0.30	4.6

 	Nurses	246	97.6%	1.4	0.27	7.4

Hospital employees who work in offices or areas removed from direct patient care should be allowed to smoke (Disagree)	Admin	76	69.7%	1.0

Physicians	196	73.7%	1.4	0.77	2.6

 	Nurses	155	61.3%	0.7	0.36	1.3

A smoke-free policy is hard to enforce (Disagree)	Admin	46	42.2%	1.0

Physicians	142	53.6%	2.1	1.28	3.5

 	Nurses	104	41.6%	1.2	0.66	2.0

Having a smoke-free policy is unfair to smokers (Disagree)	Admin	90	84.1%	1.0

Physicians	234	88.0%	2.6	1.08	6.1

 	Nurses	223	88.8%	1.2	0.47	3.1

Hospitals with smoke-free policies are likely to lose patients (Disagree)	Admin	86	79.6%	1.0

Physicians	205	77.1%	2.6	1.24	5.4

 	Nurses	186	73.5%	0.9	0.45	2.0

Smoking bans at hospitals would positively influence job performance (Agree)	Admin	59	54.6%	1.0

Physicians	190	71.7%	2.0	1.21	3.3

 	Nurses	190	75.7%	2.1	1.20	3.6

Smoking bans at hospitals would positively affect the public image of the hospital (Agree)	Admin	74	68.5%	1.0

Physicians	245	92.8%	5.5	2.79	10.8

 	Nurses	226	89.7%	3.3	1.63	6.6


Cytokine	Total papers	Total ratios	References

IL-4	6	7	Hensley et al., 2002, 2003; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Audet et al., 2012

IL-6	8	12	Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Chiu et al., 2008; Audet et al., 2012; Dibaj et al., 2012

IL-10	3	6	Hensley et al., 2002, 2003; Finkelstein et al., 2011

IL-1α	5	6	Hensley et al., 2003; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009

IL-1β	12	20	Hensley et al., 2003; Kang et al., 2003; Xie et al., 2004; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Zhao et al., 2010; Berger et al., 2011; Audet et al., 2012; Valente et al., 2012

IL-12	6	12	Hensley et al., 2002, 2003, 2006; Kiaei et al., 2006; Kim et al., 2006; Dibaj et al., 2012

TNF-α	18	39	Yoshihara et al., 2002; Hensley et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kim et al., 2006; Zhang et al., 2008; Cheroni et al., 2009; Neymotin et al., 2009; Fang et al., 2010; Takeuchi et al., 2010; Finkelstein et al., 2011; Pollari et al., 2011; Audet et al., 2012; Valente et al., 2012

GFAP	46	164	Olsen et al., 2001; Yoshihara et al., 2002; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Tsai et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Zhu and Sheng, 2011; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012

Type I total	56	241	Olsen et al., 2001; Hensley et al., 2002, 2003, 2006; Yoshihara et al., 2002; Kang et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kiaei et al., 2006; Kim et al., 2006; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Zhang et al., 2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Neymotin et al., 2009; Ringer et al., 2009; Sekiya et al., 2009; Yang et al., 2009, 2011; Fang et al., 2010; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010; Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Takeuchi et al., 2010; Tsai et al., 2010; Zhao et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Pollari et al., 2011; Audet et al., 2012; Dibaj et al., 2012; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012

Type II total	10	25	Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Finkelstein et al., 2011; Audet et al., 2012; Dibaj et al., 2012


Formulation (%)/treatment	T1	T2	T3

TV surimi	91.25	–	–

MSTM surimi	–	76.25	91.25

Cold water	–	15.00	–

Soybean-concentrated protein	4.00	4.00	4.00

Cassava starch	2.00	2.00	2.00

Cure salt	0.25	0.25	0.25

Global sausage SV 800	0.80	0.80	0.80

Cochonilha carmim	0.05	0.05	0.05

Refined salt	1.65	1.65	1.65


Attribute	Value	% of Total

Genome size (bp)	4,024,382	100.00%

DNA coding region (bp)	3,618,708	89.92%

DNA G+C content (bp)	2,845,385	70.70%

Number of replicons	1

Extrachromosomal elements	0

Total genes	3,710	100.00%

RNA genes	57	1.54%

rRNA operons	2

Protein-coding genes	3,653	98.46%

Pseudo genes	90	2.43%

Genes with function prediction	2,645	71.29%

Genes in paralog clusters	360	7.70%

Genes assigned to COGs	2,674	72.08%

Genes assigned Pfam domains	2,871	77.39%

Genes with signal peptides	1,101	29.68%

Genes with transmembrane helices	860	23.18%

CRISPR repeats	0


 Group	Dose (mg/kg)	Sleep latency (min)	Sleeping time (min)

Normal	60	8 ± 1	36 ± 3

 DZP	 3	6 ± 1*	75 ± 3*

 ME	 800	12 ± 0.5*	45 ± 2*

 ME	 1000	6 ± 1*	112 ± 3*


GO.ID	Term	p-Value

Topic 2

GO:0001054	RNA polymerase I activity	2.5e-07

GO:0043022	ribosome binding	4.8e-06

GO:0030515	snoRNA binding	5.0e-06

GO:0005524	ATP binding	6.1e-06

Topic 3

GO:0003713	transcription coactivator activity	7.6e-07

GO:0003730	mRNA 3’-UTR binding	4.6e-06

GO:0004843	ubiquitin-specific protease activity	7.7e-06

Topic 4

GO:0020037	heme binding	2.2e-19

O:0008395	steroid hydroxylase activity	5.9e-18

O:0019825	oxygen binding	6.5e-14

O:0005506	iron ion binding	9.2e-13

O:0004364	glutathione transferase activity	1.5e-12

O:0008392	arachidonic acid epoxygenase activity	1.9e-12

O:0005102	receptor binding	4.2e-11

GO:0004867	serine-type endopeptidase inhibitor activity	1.1e-10

GO:0009055	electron carrier activity	1.3e-10

GO:0070330	aromatase activity	2.6e-10

GO:0042803	protein homodimerization activity	7.4e-10

GO:0008201	heparin binding	1.5e-09

GO:0002020	protease binding	2.5e-08

GO:0051087	chaperone binding	6.0e-07

GO:0003988	acetyl-CoA C-acyltransferase activity	8.4e-07

GO:0016836	hydro-lyase activity	1.0e-06

GO:0004602	glutathione peroxidase activity	1.0e-06

GO:0004601	peroxidase activity	1.3e-06

GO:0030170	pyridoxal phosphate binding	1.6e-06

GO:0004029	aldehyde dehydrogenase (NAD) activity	2.4e-06

GO:0001848	complement binding	3.1e-06

GO:0016616	oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3.2e-06

GO:0050660	flavin adenine dinucleotide binding	3.8e-06

GO:0005507	copper ion binding	4.1e-06

GO:0016709	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	5.3e-06

GO:0032403	protein complex binding	5.7e-06

GO:0051537	2 iron, 2 sulfur cluster binding	7.8e-06


Characteristics	Total (n, %)

Number	73

Age (years)	67.0 (SD 14.1)

Sex male	52 (71.2)

Admission NIHSS score	9.3 (SD 3.2)

Admission GCS score	5.6 (SD 2.0)

Smoking	30 (41.1)

Excess alcohol consumption	22 (30.1)

Pre-existing illnesses

 Hypertension	53 (72.6)

 Diabetes	36 (49.3)

 Coronary heart disease	14 (19.2)

 Liver disease (except for hepatic cirrhosis)	0 (0)

 Kidney disease	2 (2.7)

Chest X ray	73 (100)

Chest CT	58 (79.5)

 GGOs	40/58 (69.0)

 Consolidation opacities	31/58 (53.4)

 Pleural effusions	14/58 (24.1)

 Air bronchogram	11/58 (19.0)

Tachypnea (RR ≥ 25 breaths/min)	67 (91.8)

Fever (T ≥ 37.5 °C)	43 (58.9)

PaO2/FiO2 (mmHg)	143.5 (SD 59.0)

APACHE II score	28.2 (SD 10.4)

pH value	7.38 (SD 0.57)

Acidosis (pH < 7.35)	11 (15.1)

Albumin (g/L)	26.1 (SD 9.2)

Treatment

Corticosteroids	47 (64.4)

 No respiratory response	16/47 (34.0)

 Respiratory response	31/47 (66.0)

Ventilatory support	63 (86.3)

 Non-invasive ventilation alone	14/63 (22.2)

 Non-invasive ventilation followed by intubation	16/63 (25.4)

 First line invasive ventilation	33/63 (52.4)

Time from diagnosis to corticosteroids (days)	6.5 (SD 3.5)

Outcomes

 Duration of IMV (days)	8.5 (SD 5.5)

 Hospital LOS (days)	23.0 (SD 7.0)

 Hospital mortality	29 (39.7)


Hit rate (confirmed hits with selectivity over mammalian cell cytotoxicity)	G+ve	G-ve	Fungi

CO-ADD academic hit rate	0.66%	0.21%	0.98%

Commercial hit rate	0.03%	0.008%	ND


Molecular subtypes	Immunohistochemical characterization

Luminal A	ER + and/or PR+, HER2- CK8/18+

Luminal B	ER + and/or PR+, HER2+, CK8/18+

HER2+	ER-, PR-, HER2+

basal-like	ER-, PR-, HER2- and CK 5/6+, HER1+ and/or CK14+

Unclassified	ER-, PR-, HER2-, CK 5/6-, HER1- and CK14-


Control group

Score	2 weeks	14 weeks	26 weeks

Total	-0.06	-0.05	+0.01

Symptom domain	-0.21	-0.14	-0.11

Mental domain	0.0	0.0	0.0

Function domain	+0.05	+0.02	+0.14


Jurisdiction	Health policy change in studied period	Cost sharing mechanism	References

Outpatient/Inpatient services	Pharmaceuticals

1 Czech Rep	Introduction of formal fees	Until the end of 2007, outpatient and inpatient services were free of charge. Since 2008, formal OOPs exists; a flat fee of 30 CZK (€1.2) per doctor visit, 60 CZK (€2.4) per hospital day as well as spa hotels, 90 CZK (€3.6) per ambulatory visit outside of working hours. An annual ceiling of CZK 5000 (€200) for expenses related to doctor visits and drug costs was introduced. Since 2009, a new ceiling of CZK 2500 (€100) for those below 18 and above 65 was launched. A flat fee per doctor visit for children was eliminated. Since 2012, a flat fee for hospital and spa stay was reduced to 100 CZK per stay (€3.92 EUR). The dental care is paid by OOPs too. Some groups such as poor, pregnant woman, chronically ill children, patients with infectious diseases are exempted from formal OOPs.(Exchange rate used; 1 EUR = 250 CZK)	Until 2008, some form of co-payments existed. A prescription fee of 30 CZK (1.18 EUR) per item was introduced in 2008. Since 2009, a difference between actual and reimbursement price is paid out of pocket if it is higher than prescription fee.	[3, 22]

2 Estonia	Introduction of formal fees	Since 1995, a fee of €0.30 (EEK 5) per first initial outpatient consultation at public hospitals and/or health centers exists, a free price setting for specialists. Since 2002, no fees for GP visits (except for home GP visit which is €3.2) but ambulatory specialist care at maximum fee of €3.20 (EEK 50) unless a referral within the same institution or specialty is granted. Hospital fees are implemented at 1.6 EUR per day, for up to 10 days per episode of illness. Some exemptions for children, pregnant woman and emergency care apply. (Exchange rate used; 1 EUR = 15.6 EEK)	Co-payment consist of a prescription fee of €1.30 plus the difference between actual price and reimbursement level. The general reimbursement rate is 50 % of the pharmaceutical price up to a maximum reimbursement of €12.00 (EEK 200) per prescription. The reimbursement of drugs for chronic disease, children, seniors and disabled is higher, up to 100 % .	[40, 41]

3 Hungary	Introduction of formal fees	To limited extend, some form of copayments already existed since 1989 (medical devices, spas, specialist treatment outside of standard patient’s pathway etc.). Since 2007 formal co-payments were introduced; app €1 per ambulatory visit and per hospital day. After the referendum held in 2008, they were abolished.	Since 2007 reimbursement rates have been decreased from 50 to 25 %; from 70 to 55 %; and from 90 to 85 %. For drugs with a special reimbursement of 90 %, three levels of coverage was established: 50, 70 and 90 %. For drugs fully reimbursed, a minimum €1 (300 HUF) fee per prescription was introduced. For special attentionpatients eligible for free of charge drugs, a monthly limit of 40 EUR was established. OOPs apply above that sum. Eligibility for special attention is defined by GP. (Exchange rate used; 1 EUR = 250 HUF)	[21, 34]

4 Slovakia	Introduction of formal fees	The formal copayments were introduced in 2003. Since then, app. €0.66 is paid per doctor visit and app. 1.66 EUR per hospital day, app €1.99 per emergency care visit,€0.07 per km for ambulance transport and between €4.98 and 7.30 per food and accommodation in spas. In 2006, user fees for a doctor’s visit and daily hospital stay were abolished. (Exchange rate used; 1 EUR = 40.03 SKK)	Until 2003, some form of co-payments existed. Since then €0.5 EUR prescription fee has to be paid. It was reduced to €0.17in 2006. If there is a difference between the price of the drug and the reimbursement level, patient has to cover it as well.	[11, 42]


Data collection

X-ray source	PF BL-5A

Wavelength (Å)	1.0000

Space group	P41212

Unit-cell parameters (Å)	a = b = 91.3, c = 265.4

Resolution (Å)a	20.0-2.20 (2.28-2.20)

Observed reflections	689047

Unique reflections	55949

Completeness (%)a	96.5 (81.0)

Rmerge (%)a,b	9.2 (23.9)

<I>/<σ(I) > a	55.6 (11.4)

Refinement

Resolution range (Å)	20.0-2.20

Rfactor(%)c	19.2

Rfree(%)d	23.0

Protein atoms	8020

NADPH atoms	192

Water molecules	302

r.m.s deviaton from ideal

Bond lengths (Å)	0.011

Bond angles (deg.)	1.43

Ramachandran plote

Most favored regions (%)	91.7

Allowed regions (%)	8.3


Factors	Concepts	Health professionals’ experiences, barriers and facilitators & possible improvements with regard to:

Guideline related factors	Feasibility of the recommended guideline and the protocol derived from the guideline	- Guideline- Protocol- EHR- Consults- Collaboration with other continence professionals: Informing the woman’s GP after the consult by means of a letter, Advices for referrals, diagnostics and treatments

	Compatibility of the protocol: the extent to which the recommended protocol is practical	likewise

Individual health professional factors	Competences (=skills, attitude and knowledge) needed: the extent to which the targeted health professionals have competences they need	- Competences needed- Training/educational needs- Learning experiences

	Health professionals’ engagements and satisfaction with the intervention	- Involvement & Satisfaction (both rated on a 0–10 scale)

Patient factors	Patient behaviour: patient’s response to consults	- Patient’s response to consults, advices- Factors that influence patient’s response to nurses’ care, e.g., financial issues

	Patient motivation: the targeted healthcare professional’s (perceived) ability to motivate patients to adhere	- Motivating patients to adhere

	Patient preferences: the targeted healthcare professional’s (perceived) ability to pay attention to patient preferences	- Paying attention to patient preferences

Professional interactions	Referral processes: processes for communication between the targeted healthcare professionals and targeted patients	- Nurse’s interaction with GPs- Nurse’s interaction with community pharmacists- Nurse’s interaction between GPs and community pharmacists

Incentives and resources	Financial incentives: the extent to which patients, individual health professionals and organisations have financial incentives or disincentives to adhere	- Financial issues that influenced adherence among patients, GPs and community pharmacists

	Information system: the extent to which the EHR facilitates or hinders adherence	- EHR

Capacity for organisational change	Mandate, authority and accountability for making necessary changes	- Mandate for treatment change in participating women.

	Regulations, rules, policies: the extent to which organisational regulations, rules or policies facilitate or hinder necessary changes.	- Regulations, rules and policies.

Social, political and legal factors	Payer or funder policies: the extent to which payer or funder policies may affect implementation of necessary changes	- Payer or funder policies facilitating or hindering implementation of necessary changes

	Legislation: the extent to which legislation may affect implementation of necessary changes	- Legislation affecting implementation of necessary changes


 	Clonidine group 	Clonidine and Dextromethorphan group	P value

Number of patients 	30	30	—

Initial symptoms score 	2.7 ± 1.9	3.4 ± 2.6	0.17

Age 	29.3 ± 3.5	28.9 ± 4.3	0.56

Systolic blood pressure 	125.2 ± 13.6	125.4 ± 12.5	0.67

Diastolic blood pressure	75.4 ± 10.1	74.9 ± 10.1	0.98


	Active Synchronous	Passive Synchronous	Active Synchronous	Active Asynchronous

	Congruent	Congruent	Incongruent	Congruent

FMD group

Ownership statements vs. Ownership controls	Z = -3.757; p < 0.001	Z = -3.427; p = 0.001	Z = -2.379; p = 0.017	Z = -0.880; p = 0.379

Agency statements Vs. Agency controls	Z = -3.542; p < 0.001	Z = -1.700; p = 0.089	Z = -4.019; p < 0.001	Z = -0.916; p = 0.360

Ownership statements vs. Agency statements	Z = -2.534; p = 0.011	Z = -3.082; p = 0.002	Z = -3.827; p < 0.001	Z = -2.508; p = 0.012

HC group

Ownership statements vs. Ownership controls	Z = -3.666; p < 0.001	Z = -3.626; p < 0.001	Z = -3.163; p = 0.002	Z = -0.427; p = 0.669

Agency statements vs. Agency controls	Z = -3.925; p < 0.001	Z = -0.987; p = 0.324	Z = -3.927; p < 0.001	Z = -1.442; p = 0.149

Ownership statements vs. Agency statements	Z = -3.341; p = 0.001	Z = -2.834; p = 0.005	Z = -3.788; p < 0.001	Z = -1.661; p = 0.097


Characteristic	Frequency	Percent	M (SD)	Range

Age			51.50 (14.56)	18–89

Duration of RD symptoms in years			18.84 (16.49)	0–75

Years since RD diagnosis			9.76 (11.46)	0–70

Number of RDs perparticipant

 1	1058	87%

 2	130	11%

 3	22	2%

 4	4	<1%

 5	4	<1%

Gender

 Female	935	77%

 Male	279	23%

 Other	4	<1%

Income

 under $10,000	58	5%

 $10,000–20,000	95	8%

 $20,001–30,000	118	10%

 $30,001–45,000	127	11%

 $45,001–60,000	161	14%

 $60,001–75,000	128	11%

 $75,001–90,000	107	9%

 $90,001 and above	376	32%

Race/ethnicity

 American Indian orAlaska native	11	1%

 Asian	23	2%

 Black or African American	13	1%

 Hispanic or Latino/a	31	3%

 Native Hawaiian orPacific Islander	2	6%

 White	1149	94%

 Other	31	3%


 	Tumbi hospital (%)	Dodoma hospital (%)	All (%)

Occupational injury

Needle stick (used needle)	64 (37.4)*	41 (17.8)	105 (26.2)

Blood stained sharp objects	64 (37.4)*	37 (16.1)	101 (25.2)

Blood or body fluid splash	81 (47.4)*	73 (31.7)	154 (38.4)

Blood or body fluid contact with ulcerated or abraded skin	63 (36.8)*	38 (16.5)	101 (25.2)

Human bite	45 (26.3)*	21 (9.1)	66 (16.5)

At least one occupational injury	98 (57.3)*	94 (40.9)	192 (47.9)

Managing occupational exposure

Good practice	118 (69.0)	158 (68.7)	276 (68.8)


Year	2010	2010

Group	BFM	Japanese Childhood AML Cooperative Study

Induction Therapy	ATRA+IDA+VP/CA+VP+DNR	ATRA+IDA+CA

No. of Pts	81	58

Consolidation Therapy	CA+IDA+HD-CA+VP16	HD-CA+MTZ+ATRA+PIRARUBI CIN+ACLARUBICIN

EFS (%)	73 (5 years)	91 (7 years)

OS (%)	89 (5 years)	93 (7 years)


Characteristic	mean ± SD, or N(%)

Gender

Male	85 (38.3)

Female	137(61.7)

Marital status

Married	205 (92.3)

Not married	17 (7.7)

Mean age (years)	64.5 ± 6.4

Age categories

<60	48 (21.6)

60-69	119 (53.6)

≥70	55 (24.8)

Education

Illiteracy or elementary school	21 (9.5)

Junior high school	85 (38.3)

Senior high school	64 (28.8)

Technical school or college	52 (23.4)

Family per capita month income (RMB)

<2000	102 (45.9)

≥2000	120 (54.1)

Family history of diabetes

Yes	86 (38.7)

No	136 (61.3)

Clinical symptoms

Yes	96 (43.2)

No	126 (56.8)

Complications

Yes	155 (69.8)

No	67 (30.2)

Duration of diabetes (years)

<4	64 (28.8)

5-9	72 (32.4)

10-14	56 (25.2)

≥15	30 (13.5)

Mean BMI (kg/m2)	24.9 ± 3.4

BMI categories*

<24	91 (41.0)

≥24	131 (59.0)


General recommendations	Rehabilitation should be undertaken by individuals with relevant skills and knowledge communication between teams and professionals over the rehabilitation pathway should occur

Pathway-specific recommendations

During critical care stay	Assess risk of post-ICU disability

Commence goal-oriented rehabilitation early

Involve families and carers

Provide illness-related information to patient and family

Optimise provision of nutrition

At ICU discharge	Screen patient for physical and psychological issues

Plan individualised rehabilitation programme with defined goals

Provide information to patients and families about rehabilitation pathway, likely morbidity, ICU stay, and transition to general ward environment

During ward based care	Repeat screening for physical and psychological issues

Offer individualised rehabilitation programme with defined goals, provided by a multidisciplinary team

Regularly update rehabilitation programme and goals, making specialist referral where appropriate

Offer structured self-directed and supported rehabilitation manual for at least 6 weeks to appropriate patients

Prior to hospital discharge	Perform a functional assessment including physical and psychological elements, evaluating the impact on patient activities of daily living and participation

Ensure support for outstanding issues are arranged, including ongoing rehabilitation by community services

Provide patient and family with relevant information, including information about their ICU stay

At 2–3 months post-ICU discharge	Review patient as outpatient and perform functional assessment

Refer for ongoing rehabilitation and/or specialist support according to individual need

Adapted from [36]


Variables	Frequency (percentage)

Gender (females)	212 (58.1)

Age at diagnosis (years):

 	≤ 5	24 (6.6)

 	6–10	170 (46.6)

 	11-15	171 (46.8)

Residence (urban or semi-urban):	178 (48.8)

Mitral valve disease	359 (98.4)

Pure mitral stenosis (all grades)	35 (10.0)

Mitral stenosis with regurgitation (all grades)	91 (24.9)

Mitral regurgitation, no stenosis (all grades)	233 (63.8)

Multi-valvular involvement (mitral valve disease included):

Aortic valve disease (regurgitation and/or stenosis)	257 (70.4)

Tricuspid valve disease (regurgitation and/or stenosis)	299 (81.9)

Mean transmitral diastolic pressure gradient (n = 108):

 	<10 mmHg	4 (3.5)

 	10 – 20 mmHg	40 (35.7)

 	21 – 30 mmHg	61 (54.5)

 	>30 mmHg	3 (2.7)

Mitral valve score for severe mitral stenosis (n = 19)

 	≤8	2 (10.5)

 	>8	17 (89.5)

Functional class (New York Heart Association):

 	I	10 (2.7)

 	II	276 (75.6)

 	III	27 (7.4)

 	IV	52 (14.2)

On secondary prophylaxis against recurrence of rheumatic fever (at the time of referral)	272 (74.5)


Transgene	Description	Efficacy	Promoter	Assay	Publication

R2	SIV rev + env shRNA	68%–80% inhibition of viral replication	U6	SIV challenge, CEMx174 cell line	Parket al. 2005 [77]

L2R	HIV LTR + rev miRNA cassette	>98% inhibition of viral replication	CMV	HIV challenge, U87.CD4.CXCR4 cell line	Parket al. 2009 [78]

TAR + L2R	Tat inducible HIV LTR + rev miRNA cassette + TAR	>98% inhibition of viral replication	Tat inducible LTR-Hsp fusion

TAR + R	Tat inducible rev miRNA cassette + TAR	>98% inhibition of viral replication	Tat-inducible LTR-Hsp fusion

TAR	TAR	>98% inhibition of viral replication	LTR

Sh1	anti tat/rev shRNA	4 log reduction of viral replication	U6	HIV challenge, CD34-derived macrophages	Tayloret al. 2008 [79]

C46	membrane associated fusion inhibitor	4 log reduction of viral replication	MSCV

Sh1 + C46 + RevM10	tat/rev shRNA + membrane-associated fusion inhibitor + dominant negative Rev	significantly increased relative to C46 alone	U6, MSCV, PGK	HIV challenge of protected and unprotected cells in CEMx174 cell line

C46	membrane associated fusion inhibitor	5.2-fold increase in cell survival +3.1-fold decrease in HIV p24/cell	MSCV

4 log reduction of viral replication	SFFV	SHIV challenge, CEM.NKR-CCR5 lymphocytes	Kiemet al. 2010 [27]

15–20 fold reduction of viral replication	SFFV	SHIV or HIV single viral cycle challenge, MAGI-CCR5 cell line

SI + C46	tat/rev shRNA + membrane associated fusion inhibitor	5 fold reduction of viral replication	U6, SFFV

SII + SI + R5 + C46	two tat/rev shRNAs + CCR5 shRNA + membrane associated fusion inhibitor	23 fold reduction of viral replication	H1, SFFV

4 log reduction of viral replication	SHIV challenge, CEM.NKR-CCR5 lymphocytes

SI + C46	tat/rev shRNA + C46	4 log reduction of viral replication	U6, SFFV

SII + SI + R5	two tat/rev shRNAs + CCR5 shRNA	180 fold reduction of viral replication	H1


Lesion	Age	Site	Cytomorphology	IHQ

Ganglioneuroma	80% < 10 years	Retroperitoneum, posterior mediastinum, pelvis, head and neck	Mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Ganglioneuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, mature ganglion cells, myxoid stroma, schwann cells, neurites	NSE, Syp, PS-100 (+)CK, Actin (-)

Neuroblastoma	90% < 5 years	Retroperitoneum, posterior mediastinum	Neuroblasts, rosettes, neuropil, necrosis	NSE, Syp, PS-100, NbP (+)CK, Actin (-)

Nerve Sheath Tumors	30–50 years	Posterior mediastinum, retroperitoneum, limbs	Cohesive aggregates of spindle cells, myxoid background	NSE, PS-100 (+)CK, Actin (-)

Proliferative fasciitis, Proliferative myositis	All ages	Limbs, head and neck, chest wall	Spindle cells, plump cells ganglion cell-like cells, lack of myxoid background	Vimentin, Actin, PS-100, SMA (+)Syp, CK, NSE (-)


Sliding window (SW)	Most significant result

HCV Genotype

 	 	1	2	1	2

SNPs/SW	No. of SW	SW	SW	Pvalue	Pvalue

1	4	-	-	-	-

2	3	S1.S2	S3.S4	0.0208*	0.0546

3	2	S2.S4	S2.S4	0.0540	0.1099

4	1	S1.S4	S1.S4	0.0397*	0.1585


MicroRNA	No. of brain-expressed target genes	No. of brain-expressed target genes, P<0.05	P enrichment	No. of significant targets (corr)	No. of significant pathways

miR-499-5p	286	59	0.7172	4	12

miR-708-5p	174	37	0.9265	2	1

miR-1908-5p	56	17	0.1422	1	5


Antigen	Labeled cells	Clone	Conjugate	Sourcea

CD45	Pan-leukocyte	YKIX716.13	PE	AbD Serotec

CD18	Pan-leukocyte	CA1.4E9	AF647	AbD Serotec

CD3	T cells	CA17.2A12	FITC	AbD Serotec

CD5	T cells	YKIX322.2	PE	AbD Serotec

CD4	T helper/regulatory cells, neutrophils, activated monocytes	YKIX302.9	FITC	AbD Serotec

CD8α	Cytotoxic T cell	YCATE55.9	PE	AbD Serotec

TCRαβ	T cells	CA15.8G7	None	UC-Davis

CD21	B cells	B-ly4	PE	BD-Biosciences

CD22	B cells	RFB4	PE	Abcam

CD14	Monocytes	Tük4	PE	Dako

CD34	Stem cell	1H6	PE	BD-Biosciences

MHCII	Lymphocytes, monocytes	YKIX334.2	FITC	AbD Serotec

CD11b	Neutrophils, monocytes	CA16.3E10	None	AbD Serotec

CD11c	Monocytes, neutrophils,	CA11.6A1	None	AbD Serotec

CD11d	T subset, some monocytes	CA11.8H2	None	AbD Serotec

CD1c	T subset, B subset, monocytes	CA13.9H11	None	UC-Davis

Anti-pmn	Neutrophil	CAD048A	None	VMRD

CD90 (Thy-1)	Lymphocytes, monocytes, stem cells, eosinophils	CA1.4G8	None	UC-Davis

CD61	Platelets	SZ21	PE	Beckman-Coulter


		Results of conventional RT-PCR	Total

		Positive	Negative

Results of NanoSign® Influenza A/B antigen kit	Positive	158	23	181

	Negative	41	801	842

Total	199	824	1,023


Patients with:

2 positive Criteria		Crit1+	Crit2+	Crit3+	Crit4+

	Crit2+	11

	Crit3+	75	36

	Crit4+	10	7	19

	Crit5+	9	2	4	4

3 positive Criteria		Crit12+	Crit13+	Crit14+	Crit23+	Crit24+

	Crit3+	109

	Crit4+	4	39		10

	Crit5+	9	78	5	5	8

4 positive Criteria	Crit1234+	Crit1235+	Crit1245+	Crit1345+	Crit2345+

	22	37	9	63	0

5 positive Criteria	Crit12345+

	35


No.	Group	Treatment	Radiationa	Microgravity

1	Spaceflight	Spaceflight static slot	1.92 mGy	μg

2	Spaceflight control	Spaceflight 1g-centrifuge slot	2.27 mGy	1g

3	Ground control	Ground static slot	–	1g


Characteristics	Variables	AMA (%)	STMA (%)

Gender	Male	27	26

Female	23	24

Marital status	Single (never married)	6.1	2.7

Married	32.7	40.1

Cohabitation	2	2

Separated	1.4	2.7

Divorced	5.4	1.4

Widowed	3.4	0

Level of education	No education	15.4	12.8

Primary	16.8	15.4

Secondary	16.1	17.4

Tertiary	2	4

Employment	No	36.7	33.3

Yes	14.3	15.7

Age group	40–44	2	3.3

45–49	11	7.3

50–54	12	8

55–59	8.7	10.7

60–64	6	6.7

65–69	4	6

70+	6	8

Number of years living in the city (year group)	35–39	13.3	10.7

40–44	8	10

45–49	10.7	9.3

50–54	7.3	6

55–59	4.7	6

60–64	2	2.7

65–69	2	1.3

70+	2	4

 	N = 150	 75	75


Pollutants	No. of other sites	Median correlation (range)

Fine particles and components

24-hr avg PM2.5	12b	0.88 (0.46–0.95)

24-hr avg PM2.5	3c	0.88 (0.76–0.95)

Major ions

24-hr avg SO42–	3	0.90 (0.76–0.94)

24-hr avg NO3–	3	0.88 (0.75–0.90)

Carbon

24-hr avg OC	3	0.43 (0.38–0.69)

24-hr avg EC	3	0.47 (0.37–0.52)

Metals and metalloids

24-hr avg Si	3	0.96 (0.68–0.96)

24-hr avg K	3	0.71 (0.60–0.74)

24-hr avg Ca	3	0.35 (0.30–0.37)

24-hr avg Fe	3	0.54 (0.39–0.74)

24-hr avg Cu	3	0.03 (–0.09–0.05)

24-hr avg Zn	3	0.03 (–0.02–0.11)

24-hr avg Pb	3	0.08 (0.04–0.22)

Criteria gases

8-hr max O3	13d	0.85 (0.72–0.94)

1-hr max CO	3	0.62 (0.17–0.71)

1-hr max NO2	8	0.64 (0.27–0.70)

1-hr max SO2	10	–0.03 (–0.10–0.12)

Abbreviations: avg, average; max, maximum. aThese are partial correlations, computed as the correlations between residuals from linear models for each of the pollutants that included all of the covariates in our epidemiologic models; all correlations exclude data from 4 July 2001, 4 July 2002, and 5 July 2002. bIncludes data from all sites at which PM2.5 was measured. cIncludes data from a subset of PM2.5 sites at which PM2.5 components were also measured (every 3 or 6 days). dOnly two sites other than Tudor Ave. provided year-round O3 data; restricting the analysis to these sites produced similar results: median, 0.84 (range, 0.82–0.87).


	Tertiary hospitals (n = 50) Mean (SD) score	General hospitals (n = 109) Mean (SD) score

Reduction of rate of intubation and ventilation	4.5 (1.0)	4.8 (0.7)

Reduction in need for inter-hospital transfer	4.0 (1.2)	4.7 (0.7)

Reduction in length of stay	3.9 (1.0)	4.2 (0.8)

Reduction in complication rate	3.9 (1.2)	4.3 (0.9)

Improved patient tolerance	3.9 (1.1)	4.2 (0.9)

Reduced need for sedation	3.6 (1.2)	3.5 (1.2)

Parent/Carer Satisfaction	4.0 (0.9)	3.9 (1.1)


Measurement year	2008	2010	2013

Participation

All measured children (n, % of eligible)	1142 (86)	1448 (85)	1868 (91)

Girls/boys (% of eligible)	85/86	84/85	91/90

Completed FQ (n, % of measured)	833 (73)	1085 (75)	1134 (61)

Girls/boys (% of measured)	76/70	76/74	61/61

Distribution of children according to individual socioeconomic characteristics from FQ

Maternal education % low/high	54/46	55/45	44/56

Maternal employment	79/21	82/18	85/15

% employed/not employed1


Importance of the Water Supply Issue to the Household	Percentage

Absolutely not important	10

Not important	10

Between important and not important	8

Important	38

Very important	34


	Type 1 diabetes n = 199	All controls n = 178	p value

Sex (male:female)	98:101	84:94	0.69

Age (years)	14.4 ± 1.6	14.4 ± 2.1	0.80

Height (cm)	163 ± 10	162 ± 11	0.25

Weight (kg)	60.7 ± 14.3	54.7 ± 13.8	<0.0001

BSA (m2)	1.65 ± 0.22	1.57 ± 0.23	0.0006

Insulin administration (%)

 Pump	60.8	–

 Multiple injections	30.2	–

Smoking status n (%)

 Never smoked	181 (92.8)	63 (100)

 Smoked few puffs to a whole cigarette in my life	9 (4.6)	0

 Only 2 to 3 cigarettes in my life	1 (0.5)	0

 More than 3, but fewer than 100 cigarettes in my life	1 (0.5)	0

 >100 cigarettes in my life, none in the past month	1 (0.5)	0

 >100 cigarettes in my life, some in the last month but not every day	1 (0.5)	0

 >100 cigarettes in my life, at least 1 cigarette every day during the last month	2 [1]	0

BMI (kg/m2)	22.6 ± 4.3	20.6 ± 3.7	<0.0001

SBP (mmHg)	113 ± 10	110 ± 9	0.0005

SBP z-score for height	0.2 ± 0.9	−0.1 ± 0.9	0.0011

DBP (mmHg)	62 ± 7	58 ± 7	<0.0001

DBP z-score for height	−0.3 ± 0.6	−0.6 ± 0.7	<0.0001

MBP (mmHg)	77 ± 7	75 ± 7	0.0053

PP (mmHg)	51 ± 9	52 ± 8	0.48

HR (bpm)	66 ± 9	68 ± 12	0.036

Diabetes duration (years)	7.2 ± 3.1	–	−

Glucose (mmol/l)	9.7 ± 4.4	4.7 ± 0.7	<0.0001

HbA1c (%)	0.085 ± 0.012	0.054 ± 0.002	<0.0001

HbA1c mmol/mol	84.9 ± 12.4	53.8 ± 2.4	<0.0001

Cholesterol (mmol/L)	4.3 ± 0.88	4.24 ± 0.83	0.5158

HDL cholesterol (mmol/L)	1.6 ± 0.36	1.46 ± 0.28	0.0004

LDL cholesterol (mmol/L)	2.3 ± 0.71	2.36 ± 0.74	0.6109

Triglycerides (mmol/L)	0.84 ± 0.37	0.93 ± 0.40	0.0945

Creatinine (mmol/L)	54 ± 9	56 ± 11	0.1149

eGFR (mL/min/1.73 m2)	113 ± 17	108 ± 17	0.0405


Healthcare professional	Gender	Description of Role

Respiratory Physician	Female	Assessment of COPD and comorbidities, preparation and review of COPD treatment plans

Registered Clinic Nurse	Female	Support assessments, administer aspects of treatment plan (eg smoking cessation counselling, instruction in inhaler technique, case coordination

Research Assistant	Female	Case coordination, data entry and management

General Practitioner	Male	Prepare health care plan, receive and integrate test results in between study visits, provide referrals to specialists, allied health and Respiratory HEAL


Group	≤35 years old	36-38 years old	39-40 years old	>40 years old

Variable	RC	p	RC	p	RC	p	RC	p

Laboratory outcomes

Fertilization rate	-0.001	NS	0.000	NS	0.001	NS	-0.002	NS

High quality D3 embryos	-0.001	NS	0.000	NS	0.000	NS	0.000	NS

High quality Embryo rate	-0.005	<0.01	-0.006	0.025	0.002	NS	-0.002	NS

Blastocyst formation rate	-0.005	<0.01	-0.007	0.042	0.004	NS	-0.004	NS

Transferred embryos	0.000	<0.01	0.000	NS	0.000	NS	0.000	NS

Endometrium	0.000	NS	0.000	NS	0.001	NS	0.000	NS


 	All N = 15	18 years or younger N = 25	Over 18 Years N = 18

Medication class	Number prescribed this medication	Number prescribed this medication	Number prescribed this medication

Citalopram	5 (9.1%)	2 (8.0%)	3 (10.0%)

Escitalopram	3 (5.5%)	0 (0.0%)	3 (10.0%)

Fluoxetine	39 (70.9%)	23 (92.0%)	16 (53.3%)

Paroxetine	2 (3.6%)	0 (0.0%)	2 (6.7%)

Sertraline	2 (3.6%)	0 (0.0%)	2 (6.7%)

Mirtazapine	4 (7.3%)	0 (0.0%)	4 (13.5%)


Dependent variable	Independent variables	Odds ratio	CI (95%)	P value

	Adiponectin	0.7	0.33–1.07	0.06

	Age	0.9	0.8–1.1	0.9

 PCOS	WC	0.86	0.74–1.01	0.2

	BMI	1.4	1–1.8	0.3

	25OHD	1.9	1.3–2.5	0.002


Age (mean ± SD) years	64.3 (± 3.5)

Gender male/female	12/8

Pre-op logMAR VA (mean ± SD)	1.15 ± 0.88

Post-op logMAR VA (mean ± SD)	0.55 ± 0.30

Lens statusPhakic/IOL	4/16

Duration of detachment (mean ± SD) days	6.25 ± 3.44

Quadrants detached	2.95 (± 0.75)

Location of the main breakSuperior/inferior quadrants	16/4

IOP pre-op	11.7 ± 2.6

IOP post-op	18.9 ± 4.9

IOP 2-hour post-op	16.8 ± 4.7


	Picture name	Related distractor	Unrelated distractor

Animals	Hert (deer)	Konijn	Piano

	Konijn (rabbit)	Hert	Drumstel

	Zwaan (swan)	Geit	Bus

	Geit (goat)	Zwaan	Fluit

Clothing	Jas (jacket)	Hemd	Molen

	Hemd (singlet)	Jas	Tafel

	Rok (skirt)	Trui	Neus

	Trui (sweater)	Rok	Banaan

Transportation	Auto (car)	Bus	Kanon

	Bus (bus)	Auto	Konijn

	Trein (train)	Fiets	Kast

	Fiets (bicycle)	Trein	Trui

Buildings	Kerk (church)	Fabriek	Zwaan

	Fabriek (factory)	Kerk	Zwaard

	Molen (mill)	Kasteel	Dolk

	Kasteel (castle)	Molen	Oor

Weapons	Dolk (dagger)	Zwaard	Arm

	Zwaard (sword)	Dolk	Been

	Kanon (cannon)	Pistool	Bed

	Pistool (gun)	Kanon	Kan

Kitchenware	Kan (pitcher)	Beker	Fabriek

	Beker (cup)	Kan	Pistool

	Bord (plate)	Glas	Rok

	Glas (glass)	Bord	Kerk

Furniture	Bed (bed)	Tafel	Gitaar

	Tafel (table)	Bed	Kasteel

	Bureau (desk)	Kast	Geit

	Kast (wardrobe)	Bureau	Molen

Body parts	Neus (nose)	Arm	Auto

	Arm (arm)	Neus	Peer

	Been (leg)	Oor	Appel

	Oor (ear)	Been	Beker

Fruit	Ananas (pineapple)	Banaan	Hert

	Appel (apple)	Peer	Fiets

	Banaan (banana)	Ananas	Trein

	Peer (pear)	Appel	Hemd

Music instruments	Drumstel (drums)	Gitaar	Bureau

	Gitaar (guitar)	Drumstel	Jas

	Fluit (flute)	Piano	Bord

	Piano (piano)	Fluit	Glas


Secondary disability	Selection

Difficulties managing daily life	Societal supporta in terms of different forms of housing conditions

Problems at school	Special education (school for children with intellectual development disorders, primary school level)

Psychiatric disorderb	Average cost of depression, bipolar disorder, generalized anxiety disorder and schizophrenia

Alcohol/drug abuse	Alcohol abuse and/or illicit drug use

Suicidal ideation	No separate calculation

Included in other cost references

Criminality	No separate calculation

Cost included in alcohol/drug abuse

Inappropriate sexual behaviour	Not included

Lack of data

Reduced working capacity	Productivity loss for individuals without employment

Mortality	No separate calculation

Cost included in alcohol/drug abuse

Informal caring	Productivity loss for family member/relative/significant other


Animal yields	Advantages	Disadvantages

Milk, Eggs	Easily measurable, almost complete edible	Variation in protein, fat and energy yield, analyses may be useful

Body weight gain	Easily measurable	High portion of non edible fractions in the gains

Carcass weight	Easily measurable	Contains still fractions which are not edible (e.g., bones)

Meat, edible fraction	Completely edible	Categorization and separation not easy

Edible protein	Most important objective of animal production; comparison of various methods and sources to produce protein of animal origin	Categorization of various fractions as edible and difficulties to measure; additional analytical work; variation in N/protein content


	Number (%)	Mean ± SD	Range

Patient characteristics

Age (year)	52	44.8 ± 14	22–78

Gender

 Male	34

 Female	18

Seizures at presentation	38 (73.1%)

 Antiepileptic drugs	37

 Seizure-free	20

 Recurrent seizure	18

No seizures at presentation	14 (29.9%)

Neurological function (RTOG)	52	1.19 ± 1.15	0–3

 No neurological symptoms	17 (32.7%)

 Minor neurological symptoms	21 (40.4%)

 Moderate neurological symptoms	14 (26.9%)

Professions (n = 52)

 High education	26 (50%)

 Low education	18 (34.6%)

 Retired	8 (15.4%)

Work situation (n = 52)

 Working fully	25 (48%)

 Working half time	11 (21%)

 Not working, due to illness	4 (8%)

 Retired, unrelated to illness	8 (15%)

 Students	2 (4%)

 Unemployed	2 (4%)

Changes in professional situation	19 (36%)

Tumor characteristics

Affected hemisphere

 Right	20 (38.5%)

 Left	31 (38.5%)

 Bilateral	1 (1.9%)

Tumor location	52

Non-eloquent cortex	8

Non-eloquent cortico-subcortical	12

Eloquent cortico-subcortical	32

 Insula	9

 SMAa/Pre SMA	5/2

 Primary somatosensory area	6

 Primary motor area	4

 Language area	6

Tumor volume (cm3)	50	69.3 ± 57.3	2.8–267.8

Smaller (<61 cm3)	24

Larger (>61 cm3)	26


Symptoms	Frequency	Number	Percentage

Sneezing	No symptoms	1076	69.70%

	Occasional	398	25.80%

	Frequent	69	4.50%

Cough	No symptoms	1380	89.40%

	Occasional	149	9.70%

	Frequent	14	0.90%


Compound	Concentration	Relative activity

(mM)	(%)

dl-threo-β-phenylserine	20	100

d-threo-β-phenylserine	10	0

dl-erythro-β-phenylserine	20	840

dl-threo-(2-thienyl)serine	20	530

(S)-phenylethanol	10	6.9

dl-hydroxynorvaline	20	0

l-threonine	10	0

d-threonine	10	0

l-allo-threonine	10	0

d-allo-threonine	10	0

l-serine	10	0

d-serine	10	0

l-phenylalanine	10	0

d-phenylalanine	10	0


	Controls	Earthquake victims

Measures	Mean	SD	Mean	SD

ISI	5.05	3.5	6.35	4

IUS-12	35.00	15.2	42.54	16.7

URS total score*	121.03	12.1	128.56	13.3

URS emotional uncertainty*	26.53	6.1	31.69	7.4

URS desire for control	47.22	7.2	46.13	7.7

URS cognitive uncertainty	47.41	8.5	51.10	8.9

STAI*	37.63	8.2	42.46	7.8

BDI	6.54	5.2	8.56	5.8

ASI-3 total score*	10.90	8.3	18.21	13.3

ASI-3 physical concerns	3.41	3.9	5.46	5.6

ASI-3 cognitive concerns*	4.05	3.6	6.77	5.1

ASI-3 social concerns*	3.44	3.4	6.25	5.1

EPQ-R Extraversion/Introversion	9.05	2.8	8.48	3.2

EPQ-R neuroticism*	4.46	2.7	6.33	3.3

EPQ-R psychoticism	3.22	1.9	2.67	1.5


Clinical Training Programs in	Nation	Commenced

ROMP 	ThailandThe Philippines Malaysia 	2007 (completed) 20092011

DRMP 	The Philippines Thailand 	20102010

NMP 	BangladeshThailand	20102011


Absolute power density (mean ± SE, μV2)	Relative power densitya (mean ± SE, %)

Eyes closed	Eyes open	Eyes closed	Eyes open

23.9 ± 3.5*	2.4 ± 0.2	60.8 ± 2.4*	26.0 ± 1.7


Number of familiesb	46

Number of children < 12b	Age (years)

0–3	28

3–6	27

6–12	23

Total	78

Number of children attending Mobile Crèches centerb	0–3	27

3–6	26

6–12	23

Total	76

Average duration of attendance at Mobile Crèches center (child-days per child)c	48


History	• Activity and employment status

	• Description of LBP

	• Response to previous treatment

	• Co-morbidities and medications

Examination	• Vitals (height, weight, blood pressure)

	• Orthopedic exam (Lasegue, Patrick Fabre, Kemp, Gaenslen, Femoral Nerve Stretch)

	• Neurologic exam (motor, sensory, reflex evaluation)

	• Soft tissue evaluation

Imaging	• X-ray results (obtained if clinically warranted)

	• DEXA results (obtained if clinically warranted)

Biomechanical Assessment	• Torso strength (flexion, extension)

	• Torso endurance (flexion, extension, lateral bridge)

	• Lumbar range of motion (flexion, extension, lateral bending, rotation)

Psychosocial Assessment	• Disability (modified Roland Morris)[32,33]

	• General health status (EuroQol) [34,35]

	• Fear avoidance (Fear Avoidance Beliefs Questionnaire)[36]

	• Kinesiophobia (Tampa Scale of Kinesiophobia)[37]

	• Coping style (Vanderbilt Pain Management Inventory)[38,39]

	• Pain self-efficacy (PSEQ)[40]

	• Depression (CES-D)[41,42]

Preferences	• Which modalities were preferred

	• Expectations for improvement with each modality (5 point scale)


	Study population	Respondents	Respondents having consultations concerning sickness certification at least a few times a year

	n	n	% of study population	n	% of the respondents

All	7665	5455	71	4019	74

County

Stockholm	6794	4827	71	3446	71

Östergötland	871	628	72	573	91

Sex

Women	3646	2710	74	2007	74

Men	4019	2745	68	2012	73

Educational level1

Non-specialist		1381		1046	76

Specialist		3995		2947	74

No information		79		26	33

Mean age (years)	48.2	48.3		47.7


Symptoms (Discomforts)	after 1 ED	after 2 ED	after 3 ED	n

headache	3 (8%)	7 (19%)	3 (8%)	13

light chest pain	-	-	2 (5%)	2

stomachache	-	2 (5%)	5 (14%)	7

excitation	9 (25%)	6 (17%)	8 (22%)	23

anxiety	2 (5%)	-	-	2

shaking hands	-	1 (3%)	4 (11%)	5

somnolence	-	8 (22%)	5 (14%)	13

malaise and others	3 (8%)	9 (25%)	10 (28%)	22


 	2009	2004-08	H1N1 Attributable	Rate Ratio: 2009:2004-08

British Columbia

First Nations Reserves	13.77	9.48	4.29	1.45

Other Residents	6.65	6.18	0.47	1.08

Rate Ratio:	2.07	1.53	9.13	1.35*

First Nations:Other

Manitoba

First Nations Reserves	26.84	18.44	8.40	1.46

Other Residents	11.21	10.07	1.14	1.11

Rate Ratio:	2.39	1.83	7.36	1.31*

First Nations:Other

Ontario

First Nations Reserves	16.84	11.74	5.10	1.44

Other Residents	7.35	5.54	1.81	1.33

Rate Ratio:	2.29	2.12	2.81	1.08*

First Nations:Other


Color Choice	Volunteer group	p value

HAD normal (n = 460) No. (%) Respondents	HAD anxious (n = 117) No. (%) Respondents	HAD depressed (n = 35) No. (%) Respondents

Positive	212 (46.1%)	39 (33.3%)	8 (22.9%)	Chi-square (4) = 33.656; p < 0.001

Neutral	175 (38.0%)	44 (37.6%)	9 (25.7%)

Negative	73 (15.9%)	34 (29.1%)	18 (51.4%)


Use of CAM/conventional medicine	Frequency (%)

use only CAM	166 (51.1)

use combination of CAM and conventional medicine	159 (48.9)

Total	325 (100)


	Conditioned taste aversion	Passive avoidance	Morris water maze 19°C	Morris water maze 23°C	Object recognition	Object location

Consolidation	No effect	No effect	No effect	No effect	Effect	Effect

Reconsolidation	Effect	Effect	No effect	No effect	Effect	Effect

Aversive task	+++	+++	++	+	0	0

Spatial task	No	No	Yes	Yes	No	Yes

Associative task	Yes	Yes	Yes	Yes	No	No


Week	Content and homework

1	Browser:	Psychoeducation:

	Information about panic

	Defining goals of training

	Setting up a reward list

	Mobile:	Daily diary

	Registration of current panic event (event-based)

	Daily summary of panic, avoidance, and mood

2	Browser:	Interoceptive exposure:

	Bodily symptoms in panic

	Avoidance

	Safety behaviors

	Mobile:	Respiratory interoceptive exposure exercises

	Daily diary

3	Browser:	In vivo exposure:

	Defining an anxiety hierarchy

	Mobile:	In vivo exposures

	Dizziness interoceptive exposure exercises

	Daily diary

4	Browser:	Cognitive restructuring I:

	Negative automatic thoughts

	Defining anxiety project (training schedule for exposures)

	Mobile:	In vivo exposures

	Further interoceptive exposure exercises

	Daily diary

5	Browser:	Cognitive restructuring II:

	Reality testing of automatic negative thoughts

	Mobile:	In vivo exposures

	Further interoceptive exposure exercises

	Daily diary

6	Browser:	Relapse prevention:

	Early warning signs

	Critical life events

	Evaluation of training and its aims

	Mobile:	Breathing and muscle relaxation exercises